ML20012A380
| ML20012A380 | |
| Person / Time | |
|---|---|
| Site: | Oconee, Mcguire, Catawba, McGuire, 05000000 |
| Issue date: | 01/01/1990 |
| From: | Birch M, Mcconnell T, Owen T DUKE POWER CO. |
| To: | |
| Shared Package | |
| ML15217A104 | List: |
| References | |
| PROC-900101-03, NUDOCS 9003090351 | |
| Download: ML20012A380 (62) | |
Text
. .
~
I' , .i
- 'U
~
5 .:
( 't I'
-i ,
, jq i December;29, 1989 Schject: Offsite' Dose Calculation Manual Revision 28 .;
- The: General-Office Radiation Protection Staff is transmitting to you this-date, Revision 28 of the Offsite Dose Calculation = Manual As this revision-affects the. manual's generic section, the approval of each station manager
~
has been obtained. Please update your copy No. fD , and discard the affected pages.
,, , REMOVE THESE PAGES lNSERT THESE PAGES Table of Contents No Rev. # Table of Contents Rev. 28 ill No Rev. # ill Rev. 28 3-4 No Rev. # 3-4 Rev. 28 j 3-5 No Rev. # 3 Rev. 28-3-6 Rev. 1 3-6 Rev. 28 7 Rev. 1 3-7 Rev. 28 3-8 No Rev. # 3-8 Rev. 28 l 3-9 Rev. S 3-9 Rev. 28 4
3-10 Rev. 28- H Table'3.1-1 No Rev. # Table 3.1-1 Rev. 28 Table 3.1-6 No Rev. # Table 3.1-6 Rev. 28 thru thru
/sl-' Table 3.1-9. No Rev. # Table 3.1-9 Rev. 28 ,
s/ . Table 3.1-10 (1 of 2) No Rev. # Table 3.1-10 (1 of 2) Rev. 28 l Table 3.1-11 No Rev. # Table 3.1-11 Rev. 28 l
,- thru thru l Table 3.1-30 No Rev. # Table 3.1-30 Rev. 28 I
' NOTE: As this letter, with it's attachments, contains "LOEP" information. I please insert.this letter in-front of the December 28, 1989.
Approval.Date: 12/21/89 Approval Date: I2/22/09 i Effective Date: 1/1/90 ffective Date: 1/1/90 l
. Mary k v. Birch I T. B. Owen, Manager l L Radiation' Protection Manager Catawba Nuclear Station L Approval Date: 12/21/89 Approval Date: 12/19/89 L Effective Date: 1/1/90 Effective Date: 1/1/90 rhg* *2 W _E.
L T. L. McConnell, Manager M. S. Tuckman, Manager McGuire-Nuclear Station Oconee Nuclear Station If you have any questions concerning Revision 28, please call Jim Stewart k at (704) 373-5444 O ~"M.
James "M
Stewart, Jr.
Scientist I L
Radiation Protection 9003090351 900228 PDR ADOCK 05000269 p
Enclosure PNU g,
m 3 e i'
!i '
E i
V ,/~q 9 .1 ,)i JUSTIFICATIONS FOR REVISION 28 1
[ 'These-changes to the generic section of the Off-Site-Dose Calculation.
' Ma nue l a r e madeL f or the following reasons:
, 1)-Updated Table of-Contents to agree with current page numbers.
-i 2)l Changed ~" System Radwsste. Engineer" to " System Radiation Protection Manager" to conform with current company titles.
p 3).Added Mo-99 dose calculation.paramaters to manual.
1 4)-Corrected the Cerium cow-milk and goat-milk stable l element transfer coefficient from 6,0E-04 to 1.0E-04, and changed affected tables,
- 5) Added Vegetable / Soil s. table element transfer data and associated formulas to manual
- 6) Correct several typographical errors in definitions and/or j tables,
-l u
%g :
t /.
1 s.
tj s
s i aN
?
I __._:.__..___.1______________________ --
- - -. i "' ? v di "7,-_c
'" j ) , g
( +
- 5. , ( p
.-* t t f t
h
\ ji' 4
,$ , s. ,
i b'-
4 4 L
1 4
i
~
W !1Y Olf I o c) . .
5
$g glM -
l 4
. I
~
' N b, 3
. F F
fig.
P<
+ .
i- {
.f f
.g. 4 e
ii P
w _f 5 y 1 .
S < ;!g
(
t i f I
- ci 4 t)( ..
1
c- ; ?
..,. ~
^Ui hi'; .1 jy 3 o >
u n i;,. ,,
v_ q
't 1
r 3
)
i r$. ,
6 20FFSITE DOSE CALCULATION MANUAL- .
og, FOR f DUKE POWER NUCLEAR STATIONS .
e 4
i 5
e 4
- 7
-s. .j
% .' 2
}
l 5
- 1t' 1
1 s
Y l 1
,1 e
l
'1 1
- % )
1 1
e h
. ,g y
y TABII. OF CONTENTS i
SECTION Zgg
-IhTRODUCTION. iii 1.0 E LEASE RATE CALCULATIONS 1-1 ,
1.1 LIQUID ETTLUENTS 11 1.2 GASEOUS EFTLUENTS 11 1.2.1 Noble Gases 32
.1.2.2 Radiofodines. Particulates and Others 1-2 !
t 2.0 RADI ATION MONITORING SETPOINTS 21 2.1 - LIQ'JID MON!*IVES 21 !
2.7 . GAS'MONITOES 2-1 5
. .; - o . i 3.0 DOS 1; CKJCULATj,0&* 3-1 i 3,1 LOSE N0DELS FOR H/,XIMUM EXPOSED 2NDIVIDbAL 31 !
'3.1.1 ' kl4FJ.d Ef fluer._t_
31 f J.1.2 GasecutEfflu+nts 3-2 :
5.1.2.1 Noble Gases 32 i
_- ( 3.1.2.2 Radiciodines, Particulates, and Others 3-3 ,
- 1. 3.1.3 PJrect Radiation 3-8 -
.3.2 SIMPLITIED DOSE PROJECTIONS 38 ,
3.3 TUEL CYCLE CALCULATIONS 3-9 3.3.1 Millina 3-9 3.3.2 Conversion 39
- 3. 3. 3 . Enrichment 3-9 '
3.3.4 Tuol Fabrication 3-9 3.3.5 Nuclear Power Production 3-10 ,
3.3.6 Tuol Reorocessina 3-10 >
Appendix A -
Oconee Nuclear Station Site Specific Information Appendix B - McGuire Nuclear Station Site Specific Information Appendix C -
Catawba Nuclear Station Site Specific Information Rev. 28 1 1/1/90
l fn h l i
y'
'y LIST OF TABLES
-J i
Table 1.2 1 Dose Factors for Noble Gases and Daughters Table 1.2-2 Sose Parameters for Radiofodines and ,
Radioactive Particulate, Gaseous Effluents i i
Table 3.1-1 Bioaccumulation Factors to be Used in the ;
I Absence of Site Specific Data Table 3.1 2 Ingestion Dose Factors for Adults Table 3.1-3 Ingestion Dose ~ Factors for Teenager i Table 3.1 4 Inge.stion Dose Factors for Child Table 3.1-5 I gestion Dose Ts.ctors for Infant !
Table 3.1 6 Inhalation Dosc Facters for Adult; 3 Table 3.1-7 Inhalatann Dose Factors for Teenagst l Table 3.1 8 Inhalation Deze Fastors for Child .l Table 3.1-9 Inhalation Dose Factors for Infant Table 3.1 30 External Dose Factors for Gtending un Contaminated Ground -
Tabin 3.1-11 Stable Element Transfer Data l Tcble 3.1-12 R Values Ground Pathway - all Ages i Table 3.1 13 R Values Vegetable Pethwsy - Adult
- Table 3.1-14 R Values - Vegetable Pathway - Teenag.r s Tsble 3.1-15 R Values - Vegetable Patbway - Child ;
_( Y Tabic 3.1 16 R Values Heat Prthway - Adult LV Table 3.1 Table 3.1-18 R Values - Meat Pathway - Teenager R Values Meat Pathway - Child Table 3.1.19 R Values - Cow Milk Pathway - Adult ,
Table 3.1-20 R Values Cow Milk Pathway - Teenager !
Table 3.1 21 R Values - Cow Milk Pathway - Child Table'3.1 22 R Values - Cow Milk Pathway Infant ,
Table 3.1-23 R Values - Goat Milk Pathway - Adult >
Table 3.1-24 R Values - Goat Milk Pathway - Teenager '
Table 3.1-25 R Values - Goat Milk Pathway - Child Table 3.1 R Values - Goat Milk Pathway - Infant Table 3.1-27 R Values -' Inhalation Pathway - Adult Table 3.1-28 R Values - Inhalation Pathway - Teenager
- Table 3.1-29 R Values - Inhalation Pathway - Child l' Table 3.1-30 R Values - Inhalation Pathway - Infant ,
i l
l-I e .
l O
L 11 r
1 l
l t i l
l jT INTRODUCTION q.)
The Of faite Dose Calculation Manual provides the methodology and parameters to be used in the calculation of off site doses due to radioactive liquid and i gaseous effluents to assure compliance with the dose limitations of the j Technical Specifications. These dose limitations assure that: ;
- 1) the concentration of radioactive liquid effluents from the site to the 4 unrestricted area will be limited to the concentration levels of 10CTR20, l Appendix B. Table II;
- 2) the exposures to any individual from radioactive liquid effluents will not result in doses greater than the design objectives of 10CTR50, Appe.r. dix 1; ;
- 3) the dore rate at ar.y time at the site boundary from radioactive gaseous !
effluents w111 be limited to the annual dose limits of 10CTR20 for >
unrestricted creas; and
- 4) the exposure to any individual fron, radioactive gaseous effluents will not result f.n doses greater than the design objectives of 10CFR50, Appenda 1.
t The methodolopf used to assure cosipliance with the dose limitations described (q
v; above shall also be used to prepare the radioactive liquid and gaseous efflu-ent reports required by the Technical Specifications. To assure compliance with 40CTR190 when twice the design objectives of 10CFR50,. Appendix I are exceeded, the methodology and parameters to be used in calculating the off-site dose to any individual resulting from the entire fuel cycle except mining and waste management facilities are provided in this Manual. '
The Manual also provides the methodology and parameters to be used in the calculation of radioactive liquid and gaseous effluent monitoring instrumen-tation alarm / trip setpoints to assure compliance with the concentration and dose rate limitations of the Technical Specifications. Changes to the method-ology and parameters used in this Manual shall be reviewed by a qualified re-viewer (s) and approved by the Station Manager and the System Radiation l Protection Manager prior to implementation and shall be audited by the Nuclear I Safety Review Board. Changes to this Manual shall be submitted to the Nuclear Regulatory Commission in accordance with plant Technical Specifications.
Normally GASPAR and LADTAP are used for the calculation of offsite doses but this document also describes a method for the calculation of offsite doses when GASPAR and/or LADTAP are not available.
l This Manual does not replace any station implementing procedures.
i 1.
A l Rev. 28 l 111 1/1/90 l
p 1
'S 1.0 EEWASE RATE CAICULATIONS
('~' /
.The release rate calculations presented in the following sections are , tite releace limits. Sites containing two or more units shall administrative 1y L control releases to assure that the release rate calculations limit. releases i- as stated in the Technical Specifications. Administrative controls could limit the number of releases occurring at one time and/or apportion the release rate between the units.
1.1 LIQUID EFFLUENTS To comply with Technical Specifications and to assure that the concentration of radioactive liquid effluents from the site to the unrestricted area is limited to the concentrations of 10CFR20, t.ppendix B, Table II, Column 2, the following release rate calculation shall be pertormed:
I n ,.
f :1 F + (0 I .._.1 )
fal MPC 3 i whern:
Cg = The concentration of radionuclide, 'i', in undiluted liquid offluent, in WC1/m).
MPCg = the concentration of radionuclide, 'i', from.10CFR20, Appendix B. Table
(' II, Column 2, in VCi/ml.
f: = the undiluted effluent flow from the tank, in spa.
F = the dilution flow from the site discharge structure to unrestricted area receiving waters, in gpm.
o = recirculation factor at equilibrium; this factor accounts for the fraction of discharged water reused by the station; this factor is one for stations on rivers or lakes where discharged water cannot be reused, and varies for sites where water is recirculated and is specified in the appropriate Appendix.
1.2 GASEOUS EFFLUENTS In order to comply with the Technical Specifications and to assure that the l' dose rate, at any time, in the unrestricted area due to radioauive materials l released in gaseous effluents from the site is liuited to 5500 mrem /yr to the total body and $3000 mrem /yr to the skin for the noble gases and is limited to S1500 mrem /yr to any organ for all radioiodine and for all radioactive mate-rials in particulates form and radionuclides other than noble gases with half r
lives greater than 8 days, the following release rate calculations shall be l performed. These calculations, when solved for 'f', i.e. flowrate, are the
, release rates for noble gases and for radioiodines, particulates and other l radionuclides with half-lives greater than 8 days. The most conservative of
% release rates calculated shall control the release rate.
- / \
l Q) 1-1 Revision 5 9/10/84
l l !
j g 1.2.1 Noble Guyu i
'~,) ~
l
- I Kg x l(X/Q)Q ) <500 mres/yr, and i
3 ]
s I (L g + 1.1 Mg ) [(X/Q)Qg ) <3000 mrem /yr t i where:
i Kg = The total body dose factor due to gamma emissions for each identified noble gas radionuclide, in mrom/yr per pC1/m' from Tabie 1.2 1. j L
I w The skin dose factor due to beta emissionn for each identified noble gas radienuclide, in mies/yr per pC1/e' freu Table 1.2-1.
M, = Tas air dose factor due to gawna emissions for each identified noble l gas radionuclide, in nrad/yr por pC1/m' from Table 1.2-1 (unit con- 1 vorrlon constarst of 1.1 arem/nrad converts air dose to sk.in dose). !
P,* n The dore parameter for redionuclides other than noole gaver for the inhalation pathway, in mres/yr per 901/e' and for the food and ground 1 plane pathways in m'.(arem/yr per pCi/sec) from Table 1.2 2. The dose .
factora arc based on the critical individual organ and most restrictive ;
age group (child or infant). ;
s ..
(O
(,)
QI = The release rate of radionuclides, 'i', in gaseous effluent from all !
release points at the site, in pC1/sec.
X/Q = The highest calculated annual average dispersion parameter for any area at or beyond the unrustricted area boundary.
t W = The highest calculated annual average dispersion parameter for estimating the dose to an individual at the controlling location. ;
Qg = k:Cgf + ks = 4.72E+2 Cg f where: [
Cg = the concentration of radionuclide, 'i', in undiluted gaseous effluent, ;
in pC1/m1, f = the undiluted effluent flow, in efm.
'kg = conversion factor, 2.83E+04 ml/ft 8. ,
ks = conversion factor, 6.0E+01 sec/ min.
1.2.2 Radiciodines. Particulates, and Others i 1Pg \W Q$ ) < 1500 mrem /yr
' Q,)
l where the terms are as defined above.
! 1-2 Revision 5 9/10/84 u
- 1
~g 7 x d (1 et 1)-
1.2 i .,
DOSE FACTORS FOR NO3IE GASEG AND Dr.UGNITRS*
i Total Body Gamma Air Beta Air Dose Factor Skin Dose Factor Dose Factor Dose Factor K L M N Radionuclide (ares /vrbrUCi/m') (area /vridrpCi/m') (arad/vrtdrUCi/m') (arad/ThperpCi/m')
Kr-83m 7.56E-02** ---
1.93E+01 2.88E+02 Kr-85m 1.17E+03 1.46E+03 1.23E+03 1.97E+03 Kr-85 1.61E+01 1.34E+03 1.72E+01 1.95E+03 Kr-87 5.92E+03 9.73E+03 6.17E+03 1.03E+04 Kr-88 1.47E+04 2.37E+03 1.52E+04 2.93E+03 Kr-89 1.66E+04 1.01EF04 1.73E+04 1.06E+04 Kr-90 1.56E+04 7.29E+03 1.63E+04 7.83E+03 Xe-131m 9.15E+01 4.76E+02 1.56E+02 1.11E+03 Xe-133m 2.51E+02 9.94E+02 3.27E+02 1.48E+03 Xe-133 2.94E+02 3.06E+02 3.53E+02 1.05E+03 Xe-135m 3.12E+03 7.11E+02 3.36E+03 7.39E+02 Xe-135 1.81E+03 1.86E+03 1.92E+03 2.46E+03 Xe-137 1.42E+03 1.22E+04 1.51E+03 1.27E+04 Xe-138 8.83E+03 4.13E+03 9.21E+03 4.75E+03 Ar-41 8.84E+03 2.69E+03 9.30E+03 3.28E+03 I
l
- The listed dose factors are for radionuclides that may be detected in geseous effluents.
t **7.56E-02 = 7.56 x 10 *.
l l
,_ . _ . - ~ ..
DOSE PARAMETERS FOR RADIOI0 DINES AND RADIOACTIVE PARTICUTATE GASEOUS EFFT,UENT_S*
P(I), DOSE PARAMETERS FOR RAD 1010 DINES AND RADI0 ACTIVE PARTICULATES IN GASEOUS EFFLUENTS Pathways Pathways Inhalation Food and Ground Inhalation Food and Ground
.(ares /yr per (m . ares /yr per (mres/yr per (m'. ares /yr per Radionuclide wCi/m') wCi/sec) Radionuclid_q __wC1/m') VC1/sec)
H3 1.125 E+03 2.4E+03 RU 103 6.625 E+05 1.6E+08 Alpha Act 1.100 E+08 1.8E+10 RU 106 1.432 E+07 2.0E+08 CR 51 1.698 E+04 1.1E+07 AG 110M 5.476 E+06 1.5E+10 MN 54 1.576 E+06 1.1E+09 CD 115M 2.920 E+05 5.2E+07 FE 55 1.110 E+05 1.1E+08 SN 123 3.550 E+06 3.7E+09 FE 59 1.269 E+06 7.2E+08 SN 126 1.120 E+07 1.1E+10 CO 58 1.106 E+06 5.8E+08 SB 124 3.240 E+06 1.4E+09 CO 60 7.067 E+06 4.6E+09 SB 175 2.320 E+06 9.1E+08 NI 63 8.214 E+05 3.0E+10 TE 127M 1.408 E+06 1.0E+09 ZN 65 8.399 E+04 1.8E+10 "IE 129M 1.761 E+06 1.3E+09 RB 86 1.983 E+05 2.1E+10 CS'134 1.014 E+06 5.6E+10 SR 89 2.157 E+06 1.1E+10 C3 136 1.709 E+05 5.7E+09 SR 90 1.010 E+08 1.0E+11 CS 137 9.065 E+05 5.0E+10 Y 91 2.627 E+06 5.9E+06 EA 140 1.743 E+06 2.6E+08 ZR 95 2.231 E+06 3.5E+08 CE 141 5.439 E+05 3.2E+07 NB 95 6.142 E+05 3.8E+08 CE 146 1.195 E+07 1.6E+08 MO 99 1.354 E+05 3.2E+08 1 131 1.624 E+07 1.0E+12 I 133 3.848 E+06 9.6E+09
- If SR-90 analysis is performed, use P(I) given in I-131 for unidentified cesponents. If SR-90 and I-131 analyses are performed, use P(I) given in CS-137 for unidentified co v ents. If SR-90, I-131, and CS-137 analyses are performed, use P(I) given in Zn-65 for unidentified components.
Revision 5 9/10/84 i
i
.. - - , . . - .- .. . . - . . ~ - . . -
i
/~ ^'
2.0 RADIATION MONITORING SETPOINTS k" )
Effluent radiation monitor alarm / trip setpoints shall be determined using the calculations presented in the following sections. The calculations define the i 4 relationships between.the< measured effluent activityr the maximum allowable effluent activity, the effluent flowrate, and the dilution available in the restricted area (as defined for effluent releases in the.'iechnical Specifica-tions) which must be controlled to assure that the instantaneous release rate is not exceeded.
The-setpoints shall.be determined for those monitors listed in the appropriate.
. tables of the Technical Specifications.
2.1 LIQUID MONITORS The following equation shall be used to calcult,te liquid radiation monitor setpoints:
F 5 MPC where: [
MPC = the effluent concentration li:ait implement'.nF 10CTR2D for the site, in WCi/ml.
(~h C = the radioactivity concentration in vC1/m1, in the effluent line prior to
, V dilution and subsequent release. which may be the setpoint and, if so, represents a value which, if exceeded, would result in concentrations exceeding the limits of 10CFR20 in the unrestricted area, f = the flow measured at the radiation monitor location in spa.
F = the dilution water flow as measured prior to the release point in spa.
-(Note that if no dilution is provided, C 5 MPC. Also, note that when (F) is ,
~
large compared to (f), then F + f s F.)
2.2 GAS MONITORS The following equation shall be used to calculate noble gas radiation monitor setpoints based on Xe-133:
K(X/Q)}g<500 g
Qg = 4.72E+2 C f (See Section 1.2.1)
I where:
C = the gross activity in undiluted effluent, in pCi/ml.
1
, f = the flow from the tank or building and varies for various release I sources, in efm.
2-1
f ja 1
i l 1 UK
[~l g
= f rom Table 1,2-1 for Xe-133, 2.94E+2 ares /yr per pCi/m'.
- X/Q = the highest calculated annual average dispersion parameter for I
I any-area at or beyond the unrestricted area boundary for long term j releases, j
y b 4 4 f
A I
t
' I
+
' I i
i i
\
2-2 l
, . . - < - .-,-- . __- ,,,,,- - . --w . ,
E~:
l v i 3.0 DOSE CALCULATIONS
[
L;
,3.1 DOSE MODELS FOR MAXIMUM EXPOSED INDIVIDUAL !
3.1.1 Lianid Effluents Of the possible exposure pathways in the aquatic environment, only two contri-bute significantly to the total dose; these pathways are ingestion of potable water and aquatic foods. The dose contributions, from these pathways, for measured quantities of radioactive materials identified in liquid effluents ..
released to unrestricted areas shall be calculated for the maximum exposed individual in each age group using:
m
- Atg Cgg F) i St !A sit g l 1 tal where: ,
D = the cumulative dose commitment to the total body or any organ, i t, for an individual of age group, a, from the liquid effluent (
m -
for the total time period I At g , in mrem, t=1 t
Atg= the length of the tth time period over which C gg and Fg are
, -( g) averaged for all liquid releases, in hours.
l Ogg= the average concentration of radionuclide, 'i', in undiluted liquid j effluent during time period Atg from any liquid release, in 1 pCi/ml. !
F g = the near field average dilution factor for C gg during any liquid effluent release where:
y = f0 t y+f where ,
o = recirculation factor at equilibrium; this factor accounts for the frac-tion of discharged water reused by the station. This factor is one for stations on rivers or lakes where discharged water cannot be reused '
and varies for sites where water is recirculated. It is specified in the appropriate Appendix, i
f = liquid radwaste flow, in gpm.
F = dilution flow, in spm.
A = the site related ingestion dose commitment factor for an individual "IT *
, of age group, a, to the total body or any organ, 't', for each identi-(
fled principal gamma and beta emitter, mrem /hr per UC1/ml.
A,g, = 1.1 6 05 W ,,/Dy + U,gBFg MF ait 1
3-1 i u
Vl \, where:-
)
'1.14E5 = 10'pci/yCi x 10 ml/kg + 8760 hr/yr.
8 U,,= Water consumption by age group, 1/yr.
Infant 330 child $10 toen- 510 E adult 730 D,= Dilution factor from the near field area to the potable water intake.
U,g a fish consumption by age group, kg/yr.
, infant --
child 6.9 teen 16 adult- 21 BFg = Bioaccumulation factor for radionuclide, 'i', in fish, pC1/kg per pC1/1, from Table 3.1-1.
Dr aft
= Dose conversion factor for radionuclide, 'i', by age group in pre-selected organ, t, in aree/pci, from Tables 3.1-2, 3.1-3, 3.1-4, and 3.1-5, respectively.
Using the above information, A values for the-adult'have been calculated E' for each site.' Thisinformati8d*isprovidedintheTable"X"4.0-3where"X" i is the appendix-for the site in question.
3.1.2 Gaseous Effluents The' dose contributions from nesasured quantities of radioactive materials identified in gaseous effluent released to unrestricted areas shall be cal-culated for the maximum exposed individual using the following equations:
3.1.2.1 Noble Gases For gamma radiation:
Dg = 3.17 E-8 I Mg [(X/Q) Qg )
i=1 For beta radiations s
DS = 3.17 E-8 I Ng [(X/Q) Qg ]
i=1 ,
where:
1 3.17E-08 = The inverse of the number of seconds in a year.
, Mg = The air dose factor due to gamma emissions for each identified
( noble gas radionuclide, in mrad /yr per pC1/m' from Table 1.2-1. 1 3-2 Revision 5 9/10/84
l 1
[ !
/ ; N = The air dose factor due to beta emissions for each identified l I
/ I noble gas radionuclide, in arad/yr per WCi/m from Table 1.2 1.
8
-X/Q = The highest calculated annual average relative concentration for s'y I area at or beyond the unrestricted area boundary.
Qg = The release of noble gas radionuclides, 'i', in gaseous effluents, in pCi. i
< a 3.1.2.2 Radioiodines, Particulates, and Others I These calculations apply to all radiciodines, radioactive materials in partic- !
ulate form and radionuclides other than noble gases with half-lives greater 1 than 8 days:
- l D = 3.17 E-8 I Rg [WQg )
i where: 1 3.17E-08 = The inverse of the number of seconds in a year.
r Q g = The release of radioiodines, radioactive materials in psrticalate fore and radionuclides other than noble gases in gaseous effluents, 'i', ,
v in 901. Releases shall be cumulative over the calendar quarter or year :
C as appropriate.
W = The annual average dispersion or deposition parameter for estimating the dose to an individual at the controlling location.
W = (X/Q) for the inhalation pathway, in sec/m . 8 W=(D[Q)forthefoodandgroundplanepathways,inmeters *8 8
Rg = The dose factor for each identified radionuclide, 'i', in m .(arem/yr) per pC1/sec or mrem /yr per pC1/m 8
, for each pathway. (Tables 3.1-12
- 3.1-30) where:
InhalationPathwayFactor,Rf[X/Q)
RI [X/Q) = K'(BR), (DFAg), (mrem /yr per pCi/m ) 8 where:
K' = a constant of unit conversion, 108 pCi/pC1.
(BR), = the breathing rate of the receptor of age group (a), in m /yr. 8 O
(
Thebreathingrates(BR)!1.109.for given in Regulatory Guid the various age groups are tabulated below, as 3-3 Revision 5 9/10/84
I, 6
l L .
/ - Are Group (a) Breathina Rate (a /vr) 8 1 ) !
Infant 1400 i Child 3700 i Teen 8000 '
Adult 8000 (DFA g ), = the maximum organ inhalation dose factor the receptor of age group (a) for the ith radionuclide, in arem/pC1. The total body is con-
-sidered as an organ in the selection of (DFAg ) ,. See Tables 3.1-6, .
3.1-7, 3.1-8, and 3.1-9. '
g for the various age groups are given in Tables F Inhalation.
3.1-6, 3.1-7,dose factors 3.1-8, (DFA and 3.1-9 )"(taken from Regulatory Guide 1.109 (Rev.1)).
GroundPlanePathwayFactor,Rf[D/Q)
RU [D/Q) = K'K"(SF)DFG g
[(1 e' ti )/kg) (m' + area /yr per pCi/sec) '
where: !
K' = a constant of unit conversion, 10' pCi/pC1. i K" = a constant of unit conversion, 8760 hr/ year.
i g
= the decay constant for the ith radionuclids, sec'3 t = the exposure time, 4.73 x 10' sec (15 years). '
DFGg = the ground plano dose conversion factor for the ith radionuclide .
(mrom/hr per pCi/m').
SF = the shielding factor (dimensionless), 0.7 (Regulatory Guide 1.109 (Rev.
1)).
Ground plane dose conversion factors. DFG, are found in Table 3.1-10.
Grass-Cow-HilkPathwayFactor,Rf[D/Q)
R [D/Q) = K' E QF (Uap) F,(DFL g ), [ (y y)x[ * (1-exp (-(kg + 1,)t,p)).
+
(1-f" f') B iv y (1-exp(-(1g +y l )t,,)) exp(-lght )I + P II'"*PI'1 1*b))) exp(*1ggt )
s i ,
(m' mrem /yr per pCi/sec)
O e v
, Rev. 28 3-4 1/1/90
p .-
n.
)
I .
'T where:
I
) !
K' = a constant of unit conversion, 105 pCi/DCi.
l , Qp = the cow's consumption. rate, in kg/ day-(wet weight), (Regulatory I Guide 1.109 (Rev. 1)). (Milk cow = $0, Beef Cattle = $0, Goats = 6). !
U,p = the receptor's milk consumption rate for age (a), in liters /yr. l U*E (liters /yr) - Infant 330 Child 330
- Teen 400 !
- Adult 310 (Regulatory Guide 1.109 (Rev. 1)) ;
Y E
= the agricultural productivity by unit area of pasture feed grass, !
in kg/m', 0.7. 1 Y" = the agricultural productivity by unit area of stored feed, in l kg/m*, 2.0. ,
F, = the stable element transfer coefficients, in days /li;er, Table 3.1-11. i i
r = fraction of deposited activity retained on cow's feed grass, r = 1 for radiciodine and r = 0.2 for particulates (Regulatory Guide '
1.109).
[D (DFLg )" =.the maximum organ ingestion dose factor for the ith radionuclide ,
.b. for the receptor in age gro.ip 'a'..in mree/pci. Bee Tables 3.1-2,
- 3.1-3, 3.1 4, and 3.1-5.
K g = the' decay constant for the ith radionuclide, in sec'8 1
" = the decay constant for removal of activity on leaf and plant sur-faces by weathering, 5.73 x 10 sec'8 (corresponding to a 14 day half-life).
t g = the transport time from pasture to cow, to milk, to receptor, fr.
sec 1.73 x 10' (2 days).
t g' = the transport time from pasture, to harvest, to cow, to milk, to re- ,
ceptor, in sec. 7.78 x 10' (90 days).
f P
= fraction of the year that the cow is on pasture (dimensionless),
- 1.0.
f 8
= fraction of the cow feed that is pasture grass while the cow is on pasture (dimensionless), 1.0.
E = an adjustment fraction which accounts for the fraction of radionu- !
clides in elemental form which contribute dose for this pathway, E = 0.5 for radioiodine, E = 1.0 for all others.
O('
t "E
= period of pasture grass exposure during growing season, in seconds, 2.59E+06 (corresponding to 30 days, Regulatory Guide 1.109).
Rev. 28 3-5 1/1/90
, .. - ______.___.J
m-
^
( t
= period of stored feed crop / vegetation exposure during growing
()T season, in seconds, 5.18E+06 (corresponding to 60 days, Regulatory Guide 1.109).
B gy = concentration factor for uptake of radionuclide i from soil by edible parts of crops, in pCi/Fg (wet weight) per pC1/Kg dry soil (Regulatory Guide 1.109). Sea isble 3.1 11.
p = the effective " surf ace density" for soil, in kg (dry soil)/m', 240 (Regulatory Guide 1.109),
t = peri d of long-term buildup for activity in soil, in seconds 4.73E8 b
(corresponding to 15 years, Regulatory Guide 1.109).
The concentration of tritium in milk is based on the airborne concentration rather than the deposition. Therefore, the R is based on [X/Q):
R [X/Q) = K'K'"F,QpU,p(DFLg ), [0.75(0.5/II)) (mrom/yr per WC1/m')
where K'" = a constant of unit conversion, 10' gm/kg.
11 = absolute humidity of the atmosphere, 8 gm/m', (Regulatory Guide 1.109) g 0.75 = the fraction of total feed that is water.
(
N 0.5 = the ratio of the specific activity of the feed grass water to the atmospheric water.
Grass-Cow Meat Pathway Factor, R" [D/Q)
The integrated concentration in meat follows in a similar manner to the development for the milk pathway, therefore: ,
R" [D/Q) = K' E Qp (U,p) Fg (DFL g ), [ )x[ " (1-exp (-(Ag + 1,)t,p))
+-y (1-f" f') B (1-exp(-(13 + yl )t,,)) x exp(-Aght )I + P (1-exp(*A t ))I
- ib s i exp(-kgg t ) (m' . mram/yr per UCi/sec)
Fg = the stable element transfer coefficients, in days /kg, Table 3.1.11.
U,p = the receptor's meat consumption rate for age (a), in kg/yr, o
s 3-6 Revision 28 1/1/90
s i
1 U'P (kg/yr) - Infant 0
- - Child 41 i
( ,
') - Teen
- Adult 65 110 Taken from Regulatory Guids 1.109 (Rev. 1).
j 3
i t
g
= the transport time'from pasture to cow, to meat, to receptor, in sec, l 1.73 x 10" (20 days), j t
h
= the transport time from crop field to receptor, in sec, 7.78 x 10' (90 days). !
I The concentration of tritium in meat is based on its airborne concentration ,
rather than the deposition. Therefore, the R is based on [X/Q). .
d R (X/Q) = K'K'"T gp Q U,p(DTLg ), [0.75(0.5/H)) (mrem /yr per WC1/m')
where all terms are defined above.
VegetationpathwayTactor,Rf[D/Q) l s
The integrated concentration in vegetation consumed by man follova the expres-sfon developed in the derivation of the milk factor. Han is considered to consume two typss of vegetation (fresh and stored) that differs only in the ,
-time period between harvest and consumption, therefore ,
B
, .s R = K' E (DFLg ), [y (1 exp(-(Ag u ,)t,)) + (1-exp(-A gb t ))I
- w) t v i i
-i t -A t 3
[U,f g e g g + U*f ,g e g h]
(m' mrem /yr per WCi/sec) wheret K' = a constant of unit conversion, 10' pCi/vC1. '
U = the consumption rate of fresh leafy vegetation by the receptor in age group (a), in kg/yr.
b U" = (kg/hr) - Infant- 0 i
- Child 26 '
- Teen 42
- Adult 64 S
U, = the consumption rate of stored vegetation by the receptor in age group (a), in kg/yr.
- Child 520
- Teen 630
- Adult 520 3-7 Revision 28 1/1/90
L,. .
,o f 3= the fraction of the annual intake of fresh leafy vegetation grown locally. (1.0).
f 8= the fraction of the annual intake of stored vegetation grown locally, (0.76).
t g= the average time between harvest of leafy vegetation and its consumption, in seconds, 8.6 x 106 (1 day).
th = the average time between harvest of stored vegetation and its consump-i tion, in seconds, 5.18 x 10' (60 days).
Y, = the vegetation area density, 2.0 kg/m8 .
and all other factor are previously defined.
The concentration of tritium in vegetation is basef on the airborne concentra-W tion rather than the deposition. Therefore,theRjisbasedon[X/Q):
li R [X/Q) = K'K'" Uft + U,f g (DFLg ), . (0.75(0.5/10) (mrom/yr per VCi/m'). l All terms detined previously'. I 3.1.3 Direct Radiation
{4 Direct radiation is that radiation from confined sources and does not include
,~ any external component from radioactive effluents. The point kernal method' -
has been used' to calculate offsite dose rates from radioactive neaterials i stored in the refueling water storage tanks, reactor makeup water storage
- tanks, and temporary on-site radwaste storage tanks. Dose calculations using .
this method performed for Duke Nuclear Stations indicate direct radiation ,
doses are much less than 0.01 mrom/yr, and, therefore, makes a negligible !
contribution to individual dose. Direct radiation doses will not be calcu- ,
lated routinely.-
3.2 SIMPLIFIED DOSE PROJECTIONS To estimate the cumulative dose contributions to the maximum exposed individ-ual for 31 day dose projection calculations, the calculations presented in Section 3.1 can be simplified. The simplified calculations would be for an individual in the critical population using only data for the critical pathway and critical radionuclide(s). Critical populations, critical pathways, and critica1' radionuclides have been determined for each Duke Nuclear Station from the dose calculations performed to evaluate compliance with Appendix I to ,
Simplified 31-day dose projection calculations are presented in the section on site specific information.
./
l i
(
Rev. 28 3-8 1/1/90 l
~ +- - .w---
r I
I
/ s 3.3 TUEL CYCII CALCULATIONS l
\ ] '
U In accordance with the requirements of 40CFR190, the annual dose commitment to !
any member of the general public shall be calculated to assure that doses are
,.c . limited to.25 millirent to.the . total body or any.. organ with .the exception of ,
the thyroid which is limited to 75 millirems. In accordance with the require- ,
ments of the Technical Specifications, the annual dose commitment-shall also !
be calculated any time that one of the quarterly dose limits of the Technical l Specifications is exceeded; these annual dose commitments may not just be ,
calculated for the calendar year. !
L c
The " Uranium fuel cycle" is defined in 40CFR Part 190.02(b) as:
" Uranium fuel cycle means the operations of milling or uranium ore, i
). chemical conversion of uranium, isotopic enrichment of uranium, fab- i r rication of uranium fuel, generation of electricity by a light-water- !
cooled nuclear power plant using uranium fuel, and reprocessing of spent l uranium fuel, to the extent that these directly support the production of i electrical power for public use utilizing nuclear energy, but excludes c mining operations, operations at waste disposal sites, transportation of any radioactive material in support of these operatfors, ano the reuse of :
recovered non-uranium special nuclear and by-product materials from the. ,
cycle." j t
Based on this definition of the fuel cycle and the information in 10CFRhl. :
Table S-3 and WASil-1248, the radiological impact of the following operations ;
has been assessed for Duke Nuclear Stations:
3.3.1 Mllina No milling operations occur within fifty miles of any Duke Euclear Ststion.
The increment of dose from milling operations to any individual within fifty ,
miles of any Duke Nuclear Station is negligible.
3.3.2 Conversion No uranium hexafluoride production occurs within fifty miles of any Duke !
Nuclear Station. The increment of dose from UFe production to any individual within fifty miles of any Duke Nuclear Station is negligible. ,
3.3.3 Enrichment No uranium enrichment operations occur within fifty miles of any Duke Nuclear Station. The increment of dose from enrichment operations to any individual within fifty miles of any Duke Nuclear Station is negligible.
3.3.4 Fuel Fabrication No. fuel fabrication operations occur within fifty miles of any Duke Nuclear Station. The increment of dose from fabrication operations to any individual ,
within fifty miles of any Duke Nuclear Station is negligible.
]A '
3-9 Revision 28 l 1/1/90
, -- ---.,,.,y . . . . -
r
('~N 3.3.5 Fuelear Power Production !
( ) The production of electricity for public use using light-water-cooled nuclear i
power stations results in increments of dose to individuals within fifty miles of any station due to. liquid and gaseous effluent releases and. direct radia-tion or skyshine. The increments of dose resulting from liquid and gaseous .
effluent releases will be calculated using the methodology presented in !
Sections 3.1.1 and 3.1.2. The dose from direct radiation, skyshine, and radiation from the station storage facilities has been estimated using ,
conservative assumptions (see Section 3.1.3). l, In certain situations more than one nuclear power station site may contribute 'i to the doses to be considered in making fuel cycle dose assessments in accor-dance with 40CTR190. Situations involving more than one station will be !
presented in the section on site specific information, j i
3.3.6 Fuel Reorocessina .
No fuel reprocessing operatiend occur within fifty miles of any Duke Nuclear i Station. - The =iscrement of dove from reprocessing operations to any individual ,
wittin fifty miles of any Duke Nuclear Station is negligible.
t To summerize, only dona fre.rements from nuclear power production operations (Section 3.3.5) need be considered in eniculatichu to d.$wonstrate compliance l with the requirements of 40CFR190.
.j/N ,
'% .)
L r
l 3
D i
+
i 5
)
\
Rev. 28 3-10 1/1/90 l
.---m
F p
- i. TABLE 3.1-10 (1 of 1)
.BIOACCUNULATION FACTORS TO BE USED IN THE ABSENCE OF SITE-SPECIFIC DATA 7 ) (pCi/kg per pCi/ liter)
L ,/'
TRESNWATER L
ELEMENT TIS!! INVERTEBRATE ll 9.0E-01 9.0E-01 Na 1.0E+02 2.0E 02 !
Cr 2.0E 02 2.0E 03 Mn 4.0E 02 9.0E 04 Fe 1.0E 02 3.2E 03 Co 5.0E 01 2.0E 02 Ni 1.0E 02 1.0E 02 Cu 5.0E 01 4.0E 02 Zn 2.0E 03 1.0E 04 Br 4.2E 02 3.3E 02 Rb 2.0E 03 1.0E 03
, Sr 3.0E 01 1.0E 02 Y 2.5E 01 1.0E 03 Zr 3.3E 00 6.7E 00 Nb 3.0E 04 1.0E 02 Mo 1.0E 01 1.0E 01 Tc 1.5E 01 5.0E 00 Ru 1.0E 01 3.0E C2 i Rh 1.0E 01 3.0E 02
- je~'g Te 4.0E 02 6.1E 03 1 , /_
I 1.5E 01 5.0E 00 Cs 2.0E 03 1.0E 03 Ba 4.0E 00 2.0% 02 La 2.5E 01 1.0E 03 Ce 1.00 00 1.0E 03 Pr 2.5E 01 1.0E 03 Nd 2.5E 01 1.0E 03 W 1.2E 03 1.0E 01 Np -1.0E 01 4.0E 02
- Table taken from Regulatory Ouide 1.109 (Rev.1)
TABLE 3.1-1 (1 of 1) '
t
/~%
('- ) Revision 28 1/1/90 i
TABLE 3.1-2) ['
(1 of 3)
INGESTION DOSE TACTORS TOR ADULTS ;
(MREM PER PCI INGESTED)
(~~}
b!
NUCL1DE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LL1 H 3 NO DATA 1.05E-07 1.0$E-07 1.05E-07 1.05E-07 1.0$E-07 1.05E-07 NA 24 1.70E-06 1.70E-06 1.70E-06 1.70E-06 1.70E-06 1.70E-06 1.70E 06 CR 51 NO DATA NO DATA 2.66E-09 1.59E-09 5.86E-10 3.53E-09 6.69E-07 MN 54 NO DATA 4.57E-06 8.72E-07 NO DATA 1.36E-06 NO DATA 1.40E-05
- t MN $6 NO DATA 1.15E-07 2.04E-08 NO DATA 1.46E-07 NO DATA 3.67E-06 TE 55 2.75E-06 1.90E-06 4.43E-07 NO DATA NO DATA 1.06E-06 1.09E-06 TE $9 ~ 4.34E 06 1.02E 05 3.91E-06 NO DATA NO DATA 2.85E-06 3.40E-05 .
CO 58 NO DATA 7.45E 07 1.67E-06 NO DATA NO DATA NO DATA 1.51E-05 CO 60 NO DATA 2.14E-06 4.72E-06 NO DATA NO DATA NO DATA 4.02E-05 NI 63 1.30E-04 9.01E-06 4.36E-06 NO DATA NO DATA NO DATA 1.88E-06 NI 65 5.28E-07 6.86E-08 3.13E-08 NO DATA NO DATA NO DATA 1.74E-06 '
CU 64 NO DATA 8.33E 08 3.91E-08 NO DATA 2.10E-07 NO DATA 7.10E-06 E" 65 4.84E-06 1.54E-05 6.96E-06 NO DATA 1.03E 05 NO DATA 9.70E-06 ZN 69 1.03E-08 1,97E 08 1.37E-39 M0 DATA 1.26L-08 NO DATA 2.96E-09
'lR 8'3 NO DATA NO DATA 4.02E-0E NO DATA NO DATA NO DATA 5.79E-08 BR 84 NO DATA NO DATA 5.21E-08 NO DATA NO DATA NO DATA 4.09E-13 (m
BP 85 NO DATA NO DATA 2.14E-09 NO DATA NO DATA NO DATA LT P 24 R.R 66 NO DATA 2.11E-05 9.63E-06 NO DATA RO DATA NO DATA 4. M -06 FB 88 NO DATA 6.05E-UD 3.21E-N NO DATA NO DATA NO DATA 8.368-19 RB E9 NO DA'!- 4.01E-08 2.82E-Oo P0 DATA '10 DATA NO DATA k.33E-21 3 SR 89 3.080-04 NO DATA 8.84E-06 NO DATA NO DATA NC DAT/. 4.94E-05 l SR 90 7.56E-03 NO DATA 1.8SE-0J NO DATA NO DATA NO DATA 2.19E-04 !
SR 93 5.67E-06 NO DATA 2.29E-07 NO DATA NO DATA NO DATA 2.70E-05 I SR 92 2.15E-06 NO DATA 9.30E-08 NO DATA NO DATA NO DATA 4.26E-05 1 Y 90 9.62E-09 NO DATA 2.3BE-10 NO DATA NO DATA NO DATA 1.02E-04 Y 91M 9.09E-11 NO DATA 3.52E-12 NO DATA NO DATA NO DATA 2.67E-10 Y 91 1.41E-07 NO DATA 3.77E-09 NO DATA NO DATA NO DATA 7.76E-05 i Y 92 8.45E-10 NO DATA 2.47E-11 NO DATA NO DATA NO DATA 1.48E-05 j Y 93 2.68E-09 NO DATA 7.40E-11 NO DATA NO DATA NO DATA 8.50E-05 ZR 95 3.04E-08 9.75E-09 6.60E-09 NO DATA 1.53E-08 NO DATA 3.09E-05 ZR 97 1.68E-09 3.39E-10 1.55E-10 NO DATA 5.12E-10 NO DATA 1.05E-04 I
- Table taken from Regulatory Guide 1.109 (Rev. 1) I
. TABLE 3.1-2 x (1 of 3) 1
TABLE 3.1-2 (2 of 3)
INGESTION DOSE TACTORS FOR ADULTS
[ 'T (MREM PER PCI INGESTED)
T. /
NUCLIDE BDNE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI t, 4 NB 95 6.22E-09 3.46E-09 1.86E 09 NO DATA 3.42E-09 NO DATA 2.10E-05 MO 99 NO DATA 4.31E-06 8.20E-07 NO DATA 9.76E 06 NO DATA 9.99E-06 TC 99M 2.47E-10. 6.98E-10 8.89E-09 NO DATA 1.06E-08 3.42E-10 4.13E-07 F
TC 101 2.54E-10 3.66E-10 3.59E 09 NO DATA 6.59E 09 1.87E-10 1.10E 21 RU 103 1.85E 07 NO DATA 7.97E-08 NO DATA 7.06E-07 NO DATA 2.16E-05 RU 105 1.54E-08 NO DATA 6.08E-09 NO DATA 1.99E-07 NO DATA 9.42E-06 RU 106 2.75E 06 NO DATA 3.48E 07 NO DATA 5.31E 06 NO DATA 1.78E-04 AG 110M 1.60E-07 1.48E-07 8.79E-08 NO DATA 2.91E-07 NO DATA 6.04E-05
- TE 125M 2.68E 06 9.71E-07 .3.59E-07 8.06E-07 1.09E-05 NO DATA 1.07E-05 TE 127H 6.77E 06 2.42E-06 8.25E-07 1.73E-06 2.75E-06 NO DATA 2.27E-05 TE 127 1.10E-07 3.95E-08 2.38E-08 8.15E-08 4.48E-07 NO DATA 8.68E-06 TE 129M 1.15E-05 4.29E-06 1.82E-06 3.95E-06 4.80E-05 NO DATA 5.79E-05 TE 129 3.14E-08 1.18E-08 7.65E-09 2.41E-08 1.32E-07 NO DATA 2.37E-08 TE 131H 1.73E-06 8.46E-07 7.0$E-07 1.34E 06 8.57E-06 NO DATA 8.40E-05 TE 131 1.970-08 6.23E-09 6.226-09 1.62E-08 8.63E-08 NO DATA 2479E-09 TE 132 7.520-06 1.63C-06 1.53E-06 1.80E 06 1.57E-05 NO DATA 7.71E-05
( ,-~) 1 130 7.56E-07 2.23E-06 8.80E 07 1.89E 04 '3.48E-06 NO DATA 1.92E-06 f (_ / 1 131 4.16E 06 5.95E-06 3.41E-06 1.95E-03 1.02E 05 NO DATA 1.57E-06 1 132 2.03E-07 5.43E-07 3.90E-07 1.906-05 8.65E-07 NO DATA 1.02E-07 1 133 1.42E-06 2.47E-06 7.53E-07 3.63E-04 4.31E-06 NO DATA 2.2?E-06 i 1 134 1.06E-07 2.88L-07 1.03E-07 4.99E-06 4.58E-07 NO DATA 2.51E-10 !
4-
]
1 135 4.43E-07 1.16E-06 4.28E-07 7.65E-05 1.86E-06 NO DATA 1.31E-06 {
CS.134 6.22E-05 1.48E-04 1.21E-04 NO DATA 4.79E-05 1.59E-05 2.59E-06 CS 136 6.51E-06 2.57E-05 1.85E-05 NO DATA 1.43E-05 1.96E-06 2.92E-06 CS 137 7.97E-05 1.09E-04 7.14E-05 NO DATA 3.70E-05 1.23E-05 2.11E-06 CS 138 5.52E-08 1.09E-07 5.40E-08 NO DATA 8.01E-08 7.91E-09 4.65E-13 BA 139 9.70E-08 6.91E-11 2.84E-09 NO DATA 6.46E-11 3.92E-11 1.72E-07 BA 140 2.03E-05 2.55E-08 1.33E-06 NO DATA 8.67E-09 1.46E-08 4.18E-05 BA 141 4.71E-08 3.56E-11 ~ 1.59E-09 NO DATA 3.31E-11 2.02E-11 2.22E-17 BA 142 2.13E-08 2.19E-11 1.34E-09 NO DATA 1.85E-11 1.24E-11 3.00E-26 LA 140 2.50E-09 1.26E-09 3.33E-10 NO DATA NO DATA NO DATA 9.25E-05 LA 142 1.28E-10 5.82E-11 1.45E-11 NO DATA NO DATA NO DATA 4.25E-07 CE 141 9.36E-09 6.33E-09 7.18E-10 NO DATA 2.94E-09 NO DATA 2.42E-05 O.
I
TABLE 3.1-2 1 (2 of 3) l i
< TABLE 3.1-2 !'
(3 of 3)
~ INGESTION DOSE TACTORS FOR ADULTS :
l ,~'
(MREM PER PCI INGESTED) !
N, ,S ]
NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI ,
CE 143 1.65E-09 1.22E-06 1.35E-10 NO DATA 5.37E-10 NO DATA 4.56E-05 CE 144 4.88E-07 2.04E-07 2.62E-08 NO DATA 1.21E-07 NO DATA i.65E 04 PR 143 9.20E-09 3.69E-09 4.56E-10 NO DATA 2.13E 09 NO DATA 4.03E-05 PR 144 3.01E-11 1.25E-11 1.53E-12 NO DATA 7.05E 12 NO DATA 4.33E-18 ND 147 6.29E-09 7.27E-09 4.35E-10 NO DATA 4.25E-09 NO DATA 3.49E-05 ,
W 187 1.03E-07 8.61E-08 3.01E-08 NO DATA NO DATA NO DATA 2.82E-05 NP 239 1.19E-09 1.17E-10 6.45E-11 NO DATA 3.65E-10 NO DATA 2.40E-05 P
, p"%
%/ }
t
( TABLE 3.1-2
\-
(3 of 3)
\
l TABLE 3.1-32 (1 of 3) -
INGESTION DOSE FACTORS FOR TEENAGER (MREM PER PCI INGESTED)
('~~}
' ~ '
NUCLIDE BONE LIVER T. BODY TRYROID KIDNEY LUNG GI-LLI H 3 NO DATA 1.06E-07 1.06E-07 1.06E-07 1.06E-07 1.06E 07 1.06E-07 NA 24 2.30E-06 2.30E-06 2.30E-06 2.30E-06 2.30E-06 2.30E-06 2.30E-06 CR 51 NO DATA NO DATA 3.60E-09 2.00E-09 7.89E-10 5.14E-09 6.05E-07 MN 54 NO DATA 5.90E-06 1.17E-06 NO DATA 1.76E-06 NO DATA 1.21E-05 MN $6 NO DATA 1.58E-07 2.81E-08 NO DATA 2.00E-07 NO DATA 1.04E-05 TE 55 3.78E-06 2.68E-06 6.25E-07 NO DATA NO DATA 1.70E-06 1.16E-06 TE $9 5.87E-06 1.37E-05 5.29E-06 NO DATA NO DATA 4.32E-06 3.24E-05 CO 58 NO DATA 9.72E-07 2.24E-06 NO DATA NO DATA NO DATA 1.34E-05 CO 60 NO DATA 2.81E-06 6.33E-06 NO DATA NO DATA NO DATA 3.66E-05 NI 63 1.77E-04 1.2SE-05 6.00E-06 NO DATA NO DATA NO DATA 1.99E-06 NI 65 7.49E-07 9.57E-08 4.36E-08 NO DATA NO DATA NO DATA 5.19E-07 CU 64 NO DATA 1.15E-07 5.41E-08 NO DATA 2.91E-07 NO DATA 8.92E-06 ZN 65 5.76E-06 2.00E-05 9.33E-06 NO DATA 1.2EE-05 NO DATA 8.47E-06 ZN 69 1.47E-08 2.80E-08 1.96E-09 NO DATA 1.83E-08 NO DATA 5.16E-06 BR 83 NO DATA NO DATA 5.74E-08 NO DATA NO DATA NO DATA 7.T E-34 BR 84 NO DATA NO DATA 7.22E-08 NO DATA NO DATA NO DATA L7 E 24
/D BR NO DATA NO DATA 3.05E-09 NO DATA NO DATA h0 DATA LT k ?4 I/
s RB 66 NO DATA 2.98E OS 1.40E-05 NO DATA NC DATA N6 DATA 4.l.1F-06 KB 88 NO DATA 8.52E-08 4.54E-08 NO DATA NO DATA NO DATA 7.30E-15 RB 89 NO DATA 5.50E-08 3.89E-08 NO DATA NO LATA NO DAT6 8.432-17 '
SR 89 4.40E-04 NO DATA 1.26E-05 NO DATA NC OATA NO LATA 5.24E-05 SR 90 S.303-03 NO DATA 2.05E-03 NO DATt. NO DATA No EATA 2.33E-04 SR 91 8.07E-06 HD DATA 3.21E-07 NO DATI. NO DATA NO DATA J.
~ 56E-05 SR 92 3.05E-06 NO DATA 1.30E-07 NO Dt.TA NO DATA NO DATt, 7.77E-03 Y 90 1.37E-08 HO DATA 3.69E-10 NO DATA NO DATA NO DATA 1.13E-04 r Y 91M 1.29E-10 NO DATA 4.93E-12 NO DATA NO DATA NO DATA 6.09E-09 ;
Y 91 2.01E-07 NO DATA 5.39E-09 NO DATA NO DATA NO DATA 8.24E-05 Y 92 1.21E-09 NO DATA 3.50E-11 NO DATA NO DATA ND DATA 3.32E-05 )
l l
- Taken from Regulatory Guide 1.109 (Rev. 1) l l
l s TABLE 3.1-3
) (1 of 3) l (G
1 l
~~
I TABLI 3.1-3 (2 of 3)
INGESTION DOSE FACTORS FOR TEENAGER
[~ ') (MREM PER PCI INGESTED)
\
/
NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI Y 93 3.83E-09 NO DATA 1.0$E-10 NO DATA NO DATA NO DATA 1.17E-04 ZR 95 4.12E-08 1.30E-08 8.94E-09 NO DATA 1.91E-08 NO DATA 3.00E-05 ZR 97 2.37E-09 4.69E-10 2.16E 10 NO DATA 7.11E-10 NO DATA 1.27E-04 NB 95 8.22E-09 4.56E-09 2.51E-09 NO DATA 4.42E-09 NO DATA 1.95E-05 MO 99 NO DATA 6.03E-06 1.15E-06 NO DATA 1.38E-05 NO DATA 1.08E-05 TC 99M 3.32E-10 9.26E-10 1.20E-08 NO DATA 1.38E-08 5.14E-10 6.08E-07 TC 101 3.60E-10 5.12E-10 5.03E-09 NO DATA 9.26E-09 3.12E-10 8.75E-18 RU 103 2.55E-07 NO DATA 1.09E-07 NO DATA 8.99E-07 NO DATA 2.13E-05 RU 105 2.18E-08 NO DATA 8.46E-09 NO DATA 2.75E-07 NO DATA 1.76E-05 RU 106 3.92E-06 NO DATA 4.94E-07 NO DATA 7.56E-06 NO DATA 1.88E-04 AG 110M 2.0$E-07 1.94E-07 1.18E-07 N3 DATA 3.70E-07 NO DATA 5.45E 05 TE 125M 3.83E 06 1.38E-06 5.12E-07 1.07E-06 NO DATA NO DATA 1.13E-05 TE 127H 9.67E-06 3.43E-06 1.15E-06 2.30E-06 3.92E-05 NO DATA 2.41E-05 TE 127 1.58E-07 5.60E-08 3.40E-08 1.09E-07 6.40E-07 NO DATA 1.22E-05 TE 129M 1.63E-05 6.05E-06 2.58E-06 5.26E-06 6.82E-05 NO DATA 6.12E-05 TE 129 4.48E-08 1.67E-08 1.09E-08 3.L0E-08 1.8BE-07 NO DATA 2.45E-07
,_, TE 131M 2.44E-06 1.17E Of 9.76E-07 1.1CJ-06 1.22E.05 NO DATA 9.39E-05 i 2.790-C6 1.13E-08 8.72E-09 i 1 TE 131 2.15E-08 1,22E-07 NO DATA 2.29E Q> - - . _ _ .
TE 132 3.49E 06 2.11E-06 2.08E-05 2.33E-06 2.12E NO DATA 7.00E-05 I 130 1.03E-06 2. 98E* 0ii 1.19E-06 2.43E-04 4.59E-06 NO DATA 2.29E-06 I 131 5.85E 06 8.19E-06 4.4CE*06 2.39E-05 1.41E-05 NO DATA 1.62E 06
't 132 2.770 97 L 30E-07 2.62E 07 2.46E-05 1.15E-06 FG DATA 3.13E-07 I 133 2.01L-06 3.41E-06 1. 04E'+ 06 4.76E-04 5.98E-06 NO DATA L.58E-06 I 134 1.46f-07 3.d7E-07 1,39L-07 6.45E-06 6.10E'07 NO CATA 5.10E-09 1
.- _ .., - - _ . i I 135 6.10E-07 1.57E-06 5.82E-07 1.01E-04 2.48E-06 NO DATA 1.74E-Oe CS 134 8.37E-05 1.97E-04 9.14E-05 NO DATA 6.26E-05 2.39E-05 2.45E-06 l CS 136 8.59E-06 3.38E-05 2.27E-05 NO DATA 1.84E-05 2.90E-06 2.72E-06 i CS 137 1.12E-04 1.49E-04 5.19E-05 NO DATA 5.07E-05 1.97E-05 2.12E-06 CS 138 7.76E-08 1.49E-07 7.45E-08 NO DATA 1.10E-07 1.28E-08 6.76E-11 BA 139 1.39E-07 9.78E-11 4.05E-09 NO DATA 9.22E-11 6.74E-11 1.24E-06 m
( TABLE 3.1-3 (2 of 3)
i TABLE 3.1-3 (3 of 3)
INGESTION DOSE FACTORS FOR TEENAGER l
/ (MREM PER PCI INGESTED)
') !
.)
NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI !
1 BA 140 2.84E-05 3.48E-08 1.83E-06 NO DATA 1.18E-08 2.34E-08 4.38E-05 BA 141 6.71E-08 5.01E-11 2.24E-08 NO DATA 4.65E-11 3.43E-11 1.43E-13 BA 142 2.99E-08 2.99E-11 1.84E-09 NO DATA 2.53E-11 1.99E 11 9.18E-20 LA 140 3.48E-09 1.71E-09 4.55E-10 NO DATA NO DATA NO DATA 9.82E-05 LA 142 1.79E-10 7.95E-11 1.98E-11 NO DATA NO DATA NO DATA 2.42E-06 i CE 141 1.33E-08 8.88E-09 1.02E-09 NO DATA 4.18E-09 NO DATA 2.54E 05 CE 143 2.35E-09 1.71E-06 1.91E-10 NO DATA 7.67E-10 NO DATA 5.14E-05 !
CE 144 6.96E-07 2.88E-07 3.74E-08 NO DATA 1.72E-07 NO DATA 1.75E-04 PR 143 1.31E-08 5.23E 09 6.52E-10 NO DATA 3.04E-09 NO DATA 4.31E-05 PR 144 4.30E-11 1.76E-11 2.18E-12 NO DATA 1.01E-11 NO DATA 4.74E-14 ND 147 9.38E-09 1.02E-08 6.11E-10 NO DATA 5.99E-09 NO DATA 3.68E-05 W 187 1.46E-07 1.19E-07 4.17E-08 NO DATA NO DATA NO DATA 3.22E-05 NP 239 1.76E-09 1.66E-10 9.22E-11 NO DATA 5.21E-10 NO DATA 2.67E-05
(~)
\.sd 1
I )
\_ /
TABLE 3.1-3 Revision 5 (3 of 3) 9/10/84
TABLI 3.1-40 (1 of 3)
INGESTION DOSE TACTORS FOR CHILD
< (MREM PER PCI INGESTED)
( ')
NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI H 3 NO DATA 2.03E-07 2.03E-07 2.03E-07 2.03E-07 2.03E-07 2.03E-07 NA 24 5.80E 06 5.80E-06 5.80E-06 5.80E-06 5.80E-06 5.80E-06 5.80E-06 CR 51 NO DATA NO DATA 8.90E-09 4.94E-09 1.35E-09 9.02E-09 4.72E-07 MN 54 NO DATA 1.07E 05 2.85E-06 NO DATA 3.00E-06 NO DATA 8.98E-06 MN $6 NO DATA 3.34E-07 7.54E-08 NO DATA 4.04E-07 NO DATA 4.84E-05 TE $5 1.15E-05 6.10E-06 1.89E-06 NO DATA NO DATA 3.45E-06 1.13E-06 -
TE 59 1.65E-05 2.67E 05 1.33E-05 NO DATA NO DATA 7.74E-06 2.78E-05 CO 58 NO DATA 1.80E-06 5.51E-06 NO DATA NO DATA NO DATA 1.05E-05 CO 60 NO DATA 5.29E 06 1.56E-05 NO DATA NO DATA NO DATA 2.93E-05 NI 63 5.38E-04 2.88E-05 1.83E-05 NO DATA NO DATA NO DATA 1.94E-06 NI 65 2.22E-06 2.09E-07 1.22E-07 NO DATA NO DATA NO DATA .2.56E-05 CU 64 NO DATA 2.45E-07 1.48E-07 NO DATA 5.92E-07 NO DATA 1.15E-05 ZN 65 1.37E-05 3.65E-05 2.27E-05 NO DATA 2.30E-05 NO DATA 6.41E-06 ZN 69 4.38E-08 6.33E-08 5.85E-09 NO DATA 3.84E-08 NO DATA 3.99E-06 BR 83 NO DATA NO DATA 1.71E-07 NO DATA NO DATA NO DATA LT E-24 BR 84 NO DATA NO DATA' 1.98E-07 NO DATA NO DATA NO DATA LT E-24 f ~g BR 85 NO DATA NO DATA 9.12E-09 NO DATA NO DATA NO DATA LT E-24
( ,)
BR 86 NO DATA 6.70E-05 4.12E-05 NO DATA NO DATA F,0 DATA 4.31E-06 EB 88 NO DATA 1.90E-07 1.32E*07 NO DATA NO DATA NO DATA 9.3V2-09 RB 89 NO D/.TA 1.1)E 07 1.04t-07 N3 DATA NO DATA NO DATA 1.02f.-09 SR 89 1.32E-03 NO DATA 3.77E-05 NO DATA >;0 PATA NO DA0A 5.113 0E ,
SR 90 1.70E Oi NO DATA 4.31E-03 NU DATA N0 'JATA NO DATA 2.29E-04 SR 91 2.40E-05 NO DATA 9. 0tf.' V 7 NO DATA R) PATA NO DATA 5.30E 05 SR 92 9.03E-06 NO DATA 3.62E-07 NO DATA NO DATA NO DATA 1.71E-04 Y 90 L,115 08 NO DATA 1.10E-09 NO DATA NO DATA NO DATA 1.17E-04
_._ =.
Y 91M 3.82E-10 NO DATA 1.39E-11 NO DATA F0 DATA NO DATA 7.48E-07 Y 91 6.02E-07 NO DATA 1.61E-08 NO DATA NO DATA NO DATA 8.02E-05 Y 92 3.60E-09 NO DATA 1.03E-10 NO DATA NO DATA NO DATA 1.04E-04 i
- Taken from Regulatory Guide 1.109 (Rev. 1). l TABLI 3.1-4
__ (1 of 3) l 1
l i
l l
L l TABLE 3.1-5 (2 of 3)
INGESTION DOSE TACTORS FOR CHILD l
~'s (MREM PER PCI INGESTED)
(
U
)
NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI Y 93 1.14E-08 NO DATA 3.13E-10 NO DATA NO DATA NO DATA 1.70E-04 2R 95 1.16E-07 2.55E-08 2.27E-08 NO DATA 3.65E-08 NO DATA 2.66E-05 ZR 97 6.99E-09 1.01E-09 5.96E 10 NO DATA 1.45E-09 NO DATA 1.53E-04 NB 95 2.25E-08 8.76E-09 6.26E-09 NO DATA 8.23E 09 NO DATA 1.62E-05 ,
MO 99 NO DATA 1.33E-05 3.29E-06 NO DATA 2.84E-05 NO DATA 1.10E-05 TC 99M 9.23E-10 1.81E-09 3.00E-08 NO DATA 2.63E 08 9.19E-10 1.03E 06 t TC 101 1.07E-09 1.12E-09 1.42E-08 NO DATA 1.91E-08 5.92E-10 3.56E-09 RU 103 7.31E-07 NO DATA 2.81E-07 NO DATA 1.84E-06 NO DATA 1.89E-05 '
RU 105 6.45E-08 NO DATA 2.34E-08 NO DATA 5.67E-07 NO DATA 4.21E 05 RU 106 1.17E 05 NO DATA 1.46E-06 NO DATA 1.58E-05 NO DATA 1.82E-04 AG 110M 5.39E-07 3.84E-07 2.91E-07 NO DATA 6.78E-07 NO DATA 4.33E-05 TE 125M 1.14E-05 3.09E-06 1.52E-06 3.20E-06 NO DATA NO DATA 1.10E-05 TE 127H 2.89E-05 7.78E-06 3.43E-06 6.91E-06 8.24E-05 NO DATA 2.34E-05 TE 127 4.71E-07 1.27E-07 1.01E 07 3.26E-07 1.34E-06 NO DATA 1.84E-05 .
TE 129M 4.87E-05 1.36E-05 7.56E-06 1.57E-05 1.43E-04 NO DATA 5.94E-05 TE 129 1.34E-07 3.74E-08 3.18E-08 9.56E-08 3.92E-07 NO DATA 8.34E-06 TE 131M 7.20E-06 2.49E-06 2.65E-06 5.12E-06 2.41E-05 NO DATA 1.01E-04
- '() TE 131 8.30E-08 2.53E-08 2.47E-08 6.35E-08 2.51E-07 NO DATA 4.36E-07 !
TE 132 1.01E-05 4.47E-06 5.40E-06 6.51E G6 4,13E-05 NO DATA 4.50E-05 1 130 2.92E-06 5.906-06 3.04E-06 6.50E 04 8. 62E-( 6 NO DATA 2.76E-06 1 131 1.72E-05 1.73E-03 9.83E-36 5.72E 03 a.34E 05 NO DATA 1.54E-06 I 137 8.00E 07 1.47E 06 6.76E-07 6.32E-05 2.2SE-06 NO DATA 1.73E-06 7 133 5.92E-06 7.32E-06 2.77E 06 1.36E 03 1.22E-05 NO DATA 2.95E-06 I 134 4.19E-07 7.78E-07 3.58E 07 ? ?9E -OS 1.19E-06 No DATA 5.16E-07 l
I 135 1.75E-06 3.15E 06 1.4EE-06 2.79E-04 4.63E-06 NO DATA 2.40E 06 CS 134 2.34E-04 3.84E-04 8.104-05 NO DATA 1.19E-04 4.27E-05 2.07E-06
.CS 136 2.35E-05 6.46E-05 4.10E-05 NO DATA 3.44E-05 5.13E-06 2.27E-06 ,
1 3.27E-04 3.13E-04 4.62E-05 1.02E-04 3.67E-05 1.96E-06 CS 137 NO DATA CS 138 2.2SE-07 3.17E-07 2.01E-07 NO DATA 2.23E-07 2.40E-08 1.46E-07 l BA 139 4.14E-07 2.21E-10 1.20E-08 NO DATA 1.93E-10 1.30E-10 2.39E-05 n
( ) TABLE 3.1-4
\- / (2 of 3) l 1
TABLE 3.1-4 (3 of 3) '
INGESTION DOSE FACTORS FOR CHILD .
(MREM PER PCI INGESTED) l
(>'^^)-
NUCL1DE -BONE LIVER T. BODY THYROID - - KIDNEY LUNG GI-LLI l
-BA-140- 8.31E-05 7.28E-08 4.85E-06 NO DATA 2.37E-08 4.34E-08 4.21E-05 l BA 141 2.00E-07 1.12E-10 6.51E-09 NO DATA' 9.69E-11 6.58E-10 1.14E-07 I BA'142 8.74E-08 6.29E-11 4.88E-09 NO DATA 5.09E-11 3.70E-11 1.14E-09 i LA 140 l'. 01E 3.53E-09 1.19E-09 NO DATA NO DATA NO DATA 9.84E-05 LA 142 5.24E-10 1.67E-10 5.23E NO DATA NO DATA NO DATA 3.31E-05 CE 141 3.97E-08 1 98E-08 2.94E-09
. NO DATA 8.68E-09 NO DATA 2.47E-05 CE 143 6.99E-09 3.79E-06 5.49E-10 NO DATA 1.59E-09 NO DATA 5.55E-05 CE 144 2.08E-06 6.52E-07 1.11E-07 NO DATA 3.61E-07 NO DATA 1.70E-04 PR 143 3.93E-08 1.18E 1.95E-09 NO DATA 6.39E-09 NO DATA 4.24E-05 PR 144 1.29E-10 3.99E-11 6.49E-12 NO DATA 2.11E-11 NO DATA 8.59E-08 ND 147 2.79E-08 2.26E-08 1.75E-09 NO DATA 1.24E-08 NO DATA 3.58E-05 W 187 4.29E-07 2.54E-07 1.14E-07 NO DATA NO DATA NO DATA 3.57E-05 NP 239 -5.25E-09 3.77E-10 2.65E-10 NO DATA 1.09E-09 NO DATA- 2.79E-05 kO) v
[
\
. TABLE 3.1-4 (3 of 3)
I 1
i TABLE 3.1-50 i (1 of 3) ;
INGESTION DOSE FACTORS FOR INFANT I ff)
/
(MREM PER PCI INGESTED)
GI-LLI NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG H 3 NO DATA 3.08E-07 3.08E-07 3.08E-07 3.08E-07 3.08E-07 3.08E-07 i
' NA 24 1.01E-05 1.01E-05 1.01E-05 1.01E-05 1.01E-05 1.01E-05 1.01E-05 CR 51 NO DATA NO DATA 1.41E-08 9.20E-09 2.01E-09 1.79E-08 4.11E-07 MN 54 NO DATA 1.99E-05 4.51E-06 NO DATA 4.41E-06 NO DATA 7.31E-06 MN 56 NO DATA 8.18E-07 1.41E-07 NO DATA 7.03E-07 NO DATA 7.43E-05 FE 55- 1.39E-05 8.98E-06 2.40E-06 NO DATA NO DATA 4.39E-06 1.14E-06 '
FE 59 3.08E-05 5.38E-05 2.12E-05 NO DATA NO DATA 1.59E-05 2.57E-05 CO 58 NO DATA 3.60E-06 8.98E-06 NO DATA NO DATA NO DATA 8.97E-06 CO 60 NO DATA 1.08E-05 2.55E-05 NO DATA NO DATA NO DATA 2.57E-05
' NI 63 6.34E-04 3.92E-05 2.20E-05 NO DATA NO DATA NO DATA 1.95E-06 NI 65 4.70E-06 5.32E-07 2.42E-07 NO DATA NO DATA NO DATA. 4.05E-05 CU 64 NO DATA 6.09E-07 2.82E-07 NO DATA 1.03E-06 NO DATA 1.25E-05 i ZN 65 1.84E 6.31E-05 2.91E-05 NO DATA 3.06E-05 NO DATA 5.33E-05 ZN 69 9.33E-08 1.68E-07 1.25E-08 NO DATA 6.98E-08 NO DATA 1.37E-05 BR 83 NO DATA NO DATA 3.63E-07 NO DATA NO DATA NO DATA LT E-24 BR 84 NO DATA NO DATA 3.82E-07 NO DATA NO DATA NO DATA LT E ,
[)
BR 85 NO DATA NO DATA 1.94E-08 NO DATA NO DATA NO DATA LT E-24
'xs/ RB 86 NO DATA 1.70E-04 8.40E-05 NO DATA NO DATA NO DATA 4.35E-06 L . RB 88 NO DATA 4.98E-07 2.73E-07 NO DATA NO DATA NO DATA 4.85E-07 RB 89 NO DATA 2.86E-07 1.97E-07 NO DATA NO DATA NO DATA 9.74E-08 SR 89 2.51E-03 NO DATA 7.20E-05 NO DATA NO DATA NO DATA 5.16E-05 SR 90 1.85E-02 NO DATA 4.71E-03 NO DATA NO DATA NO DATA 2.31E-04 SR 91 5.00E-05 NO DATA 1.81E-06 NO DATA NO DATA NO DATA -5.92E-05 SR 92 1.92E-05 NO DATA 7.13E-07 NO DATA NO DATA NO DATA 2.07E-04 Y 90 .8.69E-08 NO DATA 2.33E NO DATA NO DATA NO DATA 1.20E-04 .
Y 91H 8.10E-10 NO DATA 2.76E-11 NO DATA NO DATA NO DATA 2.70E-06 Y 91 1.13E-06 NO DATA 3.01E-08 NO DATA NO DATA NO DATA 8.10E-05
- Y 92 7.65E-09 NO DATA 2.15E-10 NO DATA NO DATA NO DATA 1.46E-04
- Taken from Regulatory Guide 1.109 (Rev. 1)
TABLE 3.1-5 s (1 of 3)
'J s
a _______._________________._________._____________m
TABLE 3.1-5 (2 of 3)
INGESTION DOSE FACTORS FOR INFANT (MREM PER PCI INGESTED)
NUCLIDE BONE LIVER- T.D0DY THYROID KIDNEY LUNG GI-LLI Y 93 2.43E-08 NO DATA 6.62E-10 NO DATA NO DATA NO DATA 1.92E-04 ZR 95 2.06E-07 5.02E-08 3.56E-08 NO DATA 5.41E-08 NO DATA 2.50E-05 l ZR 97 1.48E-08 2.54E-09 1.16E-09 NO DATA 2.56E NO DATA 1.62E-04
]
NB 95 4.20E-08 1.73E-08 1.00E-08 NO DATA 1.24E-08 NO DATA 1.46E-05 MO 99 NO DATA 3.40E-05 6.63E-06 NO DATA 5.08E-05 NO DATA 1.12E-05 TC 99M 1.92E-09 3.96E-09 5.10E-08 NO DATA 4.26E-08 2.07E-09 1.15E-06 TC 101 2.27E-09 2.86E-09 2.83E-08 NO DATA 3.40E-08 1.56E-09 4.86E-07 RU 103 1.48E-06 NO DATA 4.95E 07 NO DATA 3.08E-06 NO DATA 1.80E-05 RU 105 1.36E-07 NO DATA 4.5BE-08 NO DATA 1.00E-06 NO DATA 5.41E-05 RU 106 2.41E-05 NO DATA 3.01E-06 NO DATA 2.85E-05 NO DATA 1.83E-04 AG 110M 9.96E-07 '7.27E-07 4.81E-07 NO DATA 1.04E-06 NO DATA 3.77E-05 TE 125M 2.33E-05 7.79E-06 3.15E-06 7.84E-06 NO DATA NO DATA 1.11E-05 i TE 127M 5.85E-05 1.94E-05 7.08E-06 1.69E-05 1.44E-04 NO DATA 2.36E-05 TE-127 1.00E-06 3.35E-07 2.15E-07 8.14E-07 2.44E-06 NO DATA 2.10E-05 TE 129M 1.00E-04 3.43E-05 1.54E-05 3.84E-05 2.50E-04 NO DATA 5.97E-05 TE 129 2.84E-07 9.79E-08 6.63E-08 2.3BE-07 7.07E-07 NO DATA 2.27E-05 TE 131M 1.52E-05 6.12E-06 5.05E-06 1.24E-05 4.21E-05 NO DATA 1.03E-04 TE 131 1.76E-07 6.50E-08 4.94E-08 1.57E-07 4.50E-07 NO DATA 7.11E-06 TE 132 2.08E-05 1.03E-05. 9.61E-06 1.52E-05 6.44E-05 NO DATA 3.81E-05 I 130 6.00E-06 1.32E-05 5.30E-06 1.48E-03 1.45E-05 NO DATA 2.83E-06 I 131 3.59E-05 4.23E-05 1.86E-05 1.39E-02 4.94E-05 NO DATA 1.51E-06 ,
I 132 1.66E-06 3.37E-06 1.20E-06 1.58E-04 3.76E-07 NO DATA 2.73E-06 I 133 1.25E-05 1.82E-05 5.33E-06 3.31E-03 2.14E-05 NO DATA 3.08E-06 ,
I 134 8.69E-07 1.78E-06 6.33E-07 4.15E-05 1.99E-06 NO DATA 1.84E-06 i I 135 3.64E-06 7.24E-06 2.64E-06 6.49E-04 8.07E-06 NO DATA 2.62E-06 CS 134 3.77E-04 7.03E-04 7.10E-05 NO DATA 1.81E-04 7.42E-05 1.91E-06 CS 136 4.59E-05 1.35E-04 5.04E-05 NO DATA 5.38E-05 1.10E-05 2.05E-06 CS 137 5.22E-04 6.11E-04 4.33E-05 NO DATA 1.64E-04 6.64E-05 1.91E-06 CS 138 4.81E-07 7.82E-07 3.79E-07 NO DATA 3.90E-07 6.09E-08 1.25E-06 BA 139 8.81E-07 5.84E-10 2.55E-08 NO DATA 3.51E-10 3.54E-10 5.58E-05 O TABLE 3.1-5 (2 of 3)
I TABLE 3.1-5
- (3 of 3)
~
INGESTION DOSE FACTORS FOR IhTANT
( 'NL (MREM PER PCI INGESTED) ,
'(J -
NUCLIDE BONE LIVER T. BODY THIROID KIDNEY LUNG GI-LLI BA 140 1.71E-04 1.71E-07 8.81E-06 NO DATA 4.06E-08 1.05E-07 4.20E-05 BA 141 4.25E-07 2.91E-10 1.34E-08 NO DATA 1.75E-10 1.77E-10 5.19E-06 BA 142 1.84E-07 1.53E-10 -9.06E-09 NO DATA 8.81E-11 9.26E-11 7.59E-07 .
LA.140 2.11E-08 8.32E-09 2.14E-09 NO DATA NO DATA NO DATA 9.77E-05 LA 142 1.10E-09 4.04E-10 9.67E-11 NO DATA NO DATA NO DATA 6.86E-05 CE 141 7.87E-08 4.80E-08 5.65E-09 NO DATA 1.48E-08 NO DATA 2.48E-05 CE 143 1.48E-08 9.82E-06 1.12E-09 NO DATA 2.86E-09 NO DATA 5.73E-05 CE 144 2.98E-06 1.22E-06 1.67E-07 NO DATA 4.93E-07 NO DATA 1.71E-04 PR 143 8.13E-08 3.04E-08 4.03E-09 NO DATA 1.13E-08 NO DATA 4.29E-05 PR 144 2.74E-10 1.06E-10 1.38E-11 NO DATA 3.84E-11 NO DATA 4.93E-06 ND 147 5.53E-08 5.68E-08 3.48E-09 NO DATA 2.19E-08 NO DATA- 3.60E-05 W 187 9.03E-07 6.28E-07 2.17E-07 NO DATA NO DATA NO DATA 3.69E-05 NP 239 1.11E-08 9.93E-10 5.61E-10 NO DATA 1.98E-09 NO DATA 2.87E-05 O
J rA8tE 3.1-5
([']) (3 of 3)
TABLE 3.1-6* 1 (1 of 1) !
INilALATION DOSE FACTORS FOR ADULTS
. ('"} (MREM PER PCI' INHALED) j
, N~ ! ,
l NUCLIDE BONE. LIVER T. BODY Tl!YROID KIDNEY LUNG GI-LLI' 'I 11 3 NO DATA 1.58E-07 1.58E-07 1.58E-07 1.58E-07 1.58E-07 1.58E-07 CR 51 NO DATA NO DATA 1.25E-08 7.44E-09 2.85E-09 1.80E-06 4.15E-07 l l
MN 54 NO DATA 4.95E-06 7.87E-07 NO DATA 1.23E-06 1.75E-04 9.67E-06 FE 55 3.07E-06 2.12E-06 4.93E-07 NO DATA NO DATA 9.01E-06 7.54E-07 FE 59 1.47E-06 3,47E-06 1.32E-06 NO DATA NO DATA 1.27E-04 2.35E-05 l CO 58 NO DATA 1.98E-07 2.59E-07 NO DATA NO DATA 1.16E-04 1.33E-05 CO 60 NO DATA 1.44E-06 1.85E-06 NO DATA NO DATA 7.46E-04 .3.56E-05 ZN 65- 4.05E-06 1.29E-05 5.82E-06 NO DATA 8.62E-06 1.08E-04 6.68E-06 SR 89 3.80E-05 NO DATA 1.09E-06 NO DATA NO DATA 1.75E-04 4.37E-05 SR 90 1.24E-02 NO DATA 7.62E-04 NO DATA NO DATA 1.20E-03 9.02E-05 ZR 95 1.34E-05 4.30E-06 2.91E-06 NO DATA 6.77E-06 2.21E-04 1.88E-05 MO 99 NO. DATA 1.51E-08 2.87E-09 NO DATA 3.64E-08 1.14E-05 3.10E-05 SB 124 3.90E-06 7.36E-08 1.55E-06 9.44E-09 NO DATA 3.10E-04 5.08E-05 I 131 3.15E-06 4.47E-06 2.56E-06 1.49E-03 7.66E-06 NO DATA 7.85E-07 I 133 1.08E-06 1.85E-06 5.65E-07 2.69E-04 3.23E-06 NO DATA 1.11E-06 CS 134 4.66E-05 1.06E-04 9.10E-05 NO DATA 3.59E-05 1.22E-05 1.30E-06 jy CS 136 CS 137 4.88E-06 1.83E-05 5.98E-05 7.76E-05 1.38E-05 NO DATA 1.07E-05 1.50E-06 1.46E ,
i, / 5.35E-05 NO DATA 2.78E-05 9.40E-06 1.05E-06 BA 140 4.88E-06 6.13E-09 3.21E-07 NO DATA 2.09E-09 1.59E-04 2.73E-05 CE 141 2.49E-06 1.69E-06 1.91E-07 NO DATA 7.83E-07 4.52E-05 1.50E-05 CE 144 4.29E-04 1.79E-04 2.30E-05 NO DATA 1.06E-04 9.72E-04 1.02E-04
- Table taken'from NUREG-0597 .
A iv)
TABLE 3.1-6 Rev. 28 (1 of 1) 1/1/90
[
TABLE 3.1-7*
(1 of 1)
^
INHALATION DOSE FACTORS FOR TEENAGER (N (MREM PER PCI INHALED)
()
NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNU - GI-LLI H 3 NO DATA 1.59E-07 1.59E-07 1.59E-07~ 1.59E-07 1.59E-07 1.59E-07 CR 51 NO DATA- NO DATA 1.69E-08 9.37E-09 3.84E-09 2.62E-06 3.75E-07 MN 54 NO DATA 6.39E-06 1.05E-06 NO DATA 1.59E-06 2.48E-04 8.35E-06 FE 55 4.18E-06 2.98E-06 6.93E-07 NO DATA NO DATA 1.55E-05 7.99E-07 FE 59- 1.99E-06 4.62E-06 1.79E-06 NO DATA NO DATA 1.91E-04 2.23E-05 CO 58 NO DATA 2.59E-07 3.47E-07 NO DATA NO DATA 1.68E-04 1.19E-05 CO 60 NO DATA 1.89E-06 2.48E-06 NO DATA NO DATA 1.09E-03 3.24E-05 ZN'65 4.82E-06 1.67E-05 7.80E-06 NO DATA 1.08E-05 1.55E-04 5.83E-06 SR 89 5 43E-05
. NO DATA 1.56E-06 NO, DATA NO DATA 3.02E-04 4.64E-05 SR 90 1.35E-02 NO DATA 8.35E-04 NO DATA NO DATA -2.06E-03 9.56E-05 ZR 95 1.82Ea05 5.73E-06 3.94E-06 NO DATA 8.42E-06 3.36E-04 1.86E-05 MO 99 NO DATA 2.11E-08 4.03E-09 NO DATA 5.14E-08 1.92E-05 3.36E-05 l SB 124 5.38E-06 9.92E-08 2.10E-06 1.22E-08 NO DATA 4.81E 4.98E-05 I 131 4.43E-06 6.14E-06 3.30E-06 1.83E-03 1.05E-05 NO DATA 8.11E-07 I 133 1.52E-06 2.56E-06 7.78E-07 3.65E-04 4.49E-06 NO DATA 1.29E-06 CS 134 6.28E-05 1.41E-04 6.86E-05 NO DATA 4.69E-05 1.83E-05 1.22E-06' LO CS 136 6.44E-06 2.42E-05 1.71E-05 NO DATA 1.38E-05 2.22E-06 1.36E-06 l D' = CS 137 8.38E-05 1.06E-04 3.89E-05 NO DATA 3.80E-05 1.51E-05 1.06E-06 BA 140 6.84E-06 8.38E 4.40E-07 NO DATA 2.85E-09 2.54E-04 2.86E-05 l CE 141 3.55E 2.37E-06 2.71E-07 NO DATA 1.11E-06 7.67E-05 1.58E-05 CE'144 6.11E-04 2.53E-04 3.28E-05 NO DATA 1.51E-04 1.67E-03 1.08E-04 e
- Table taken from NUREG-0597 L
l TABLE 3.1-7 Rev. 28 i, (1 of 1) 1/1/90 i L
l
TABLE-3.1-8* '
(1 of 1) '
INHALATION DOSE FACTORS FOR CHILD jg (MREM PER PCI INHALED)
Ef NUCLIDE BONE LIVER- T. BODY TRYROID KIDNEY LUNG- GI-LLI ,
H 3 NO DATA 3.04E-07 3.04E-07 3.04E-07 3.04E-07 3.04E-07 3.04E-07 '
CR 51 NO DATA NO DATA 4.17E-08 2.31E 6.57E-09 4.59E-09 2.93E-07 MN 54 NO DATA- 1.16E-05 2.57E-06 NO DATA 2.71E-06 4.26E-04 6.19E-06 FE 55 1.28E-05 6.80E-06 2.10E-06 NO DATA NO DATA 3.00E-05 7.75E-07 FE 59 5.59E-06 9.04E-06 4.51E-06 NO DATA NO DATA 3.43E-04 1.91E-05 CO 58 NO DATA 4.79E-07 8.55E-07 NO DATA NO DATA 2.99E-04 9.29E-06 CO 60 NO DATA 3.55E-06 6.12E-06 NO DATA NO DATA 1.91E-03 2.60E-05 ZN 65 1.15E-05 3.06E-05 1.90E-05 NO DATA 1.93E-05 2.69E-04 .4.41E-06 SR 89 1.62E-04 NO DATA 4.66E-06 NO DATA NO DATA 5.83E-04 4.52E-05 SR 90 2.73E-02 NO DATA 1.74E-03 ~NO DATA NO DATA 3.99E-03 9.28E-05 ZR 95 5.13E-05 1.13E-05 1.00E-05 NO DATA 1.16E-05 6.03E-04 1.65E-05 MO 99 NO DATA 4.66E-08 1.15E-08 NO DATA 1.06E-07 3.66E-05 3.42E-05' l SB 124 1.55E-05 2.00E-07 5.41E-06 3.41E-08 NO DATA 8.76E-04 4.43E-05 I 131 1.30E-05 1.30E-05 7.37E-06 4.39E-03 2.13E-05 NO DATA 7.68E-07 I 133 4.48E-06 5.49E-06 2.08E-06 1.04E-03 9.13E-06 NO DATA 1.48E-06 CS 134 1.76E-04 2.74E-04 6.07E-05 NO DATA 8.93E-05 3.27E-05 1.04E-06 IT CS 136 1.76E-05 4.62E-05 3.14E-05 NO DATA 2.58E-05 3.93E-06 1.13E-06
( J- -CS 137 2.45E-04 2.23E-04 3.47E-05 NO DATA 7.63E-05 2.81E-05' 9.78E-07 BA 140 2.00E-05 1.75E-08 1.17E NO DATA 5.71E-09 4.71E-04 2.75E-05 ,
CE 141 1.06E-05 5.28E-06 7.83E-07 NO DATA 2.31E-06 1.47E-04 -1.53E-05 CE'144 1.83E-03 5.72E-04 9.77E-05 NO-DATA 3.17E-04 3.23E-03 1.05E-04
- Table taken From NUREG-0597.
'O
-,)
~-
TABLE 3.1-8 Rev. 28 (1 of 1) 1/1/90
, : i it ,
< TABLE 3,1-90 (1 of 1)
. INHALATION DOSE FACTORS FOR INFANT
/] (MREM PER PCI INHALED)
NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LII
.H- 3 NO DATA 4.62E-07 4.62E-07 4.62E-07 4.62E-07 4.62E-07 4.62E-07 CR 51 NO DATA NO DATA 6.39E-08 4.11E-08 9.45E-09 9.17E-06 2.55E MN 54 NO DATA 1.81E-05 3.56E-06 NO DATA 3.56F. 06 7.14E-04 5.04E-06 FE 55 1.415-05 8.39E-06 2.38E-06 NO DATA NO DATA 6.21E-05 7.82E-07 FE 59- 9.69E-06 1.68E-05 6.77E-06 No DATA NO DATA 7.25E-04 1.77E-05 ,
CO 58 NO DATA 8.71E-07 1.30E-06 NO DATA NO DATA 5.55E-04 7.95E-06 CO 60 NO DATA- 5.73E-06 8.41E-06 NO DATA NO DATA- 3.22E-03 2.28E-05 ZN 65 1.38E-05 4.47E-05 2.22E-05 NO DATA 2.32E-05 4.62E-04 3.67E-05 SR 89 2.84E-04 NO DATA 8.15E-06 NO DATA NO DATA 1.45E-03 4.57E SR 90 2.92E-02 NO DATA 1.85E-03 NO DATA NO DATA 8.0,3E-03 9.36E-05 ZR 95 8.24E-05 1.99E-05 1.45E-05 NO DATA 2.22E-05 1.25E-03 1.55E-05 MO 99 NO DATA 1.18E-07 2.31E-08 NO DATA 1.89E-07 9.63E-05 3.48E-05 l 1 SB 124 2.71E-05 3.97E-07 8.56E-06 7.18E-08 NO DATA 1.89E-03 4.22E I 131 2.71E-05 3.17E-05 1.40E-05 1.06E-02 3.70E-05 NO DATA 7.56E-07 I 133 9.46E-06' 1.37E-05 4.00E-06 2.54E-03 1.60E-05 NO DATA 1.54E-06 1
L CS 134 2.83E-04 5.02E-04 5.32E-05' NO DATA 1.36E-04 5.69E-05 9.53E-07 CS 136 3.45E-05 9.61E-05 3.78E-05 NO DATA 4.03E-05 8.40E-06 1.02E-06
('~') CS 137 3.92E-04 4.37E-04 3.25E-05 NO DATA 1.23E-04 '5.09E-05 9.53E-07 m BA 140~ 4.00E-05 4.00E-08 2.07E-06 NO DATA 9.59E-09' 1.14E-03 2.74E-05 L
u CE 141 1.98E-05 1.19E-05 1.42E-06 NO DATA 3.75E-06 3.69E-04 1.54E-05 l CE 144 2.28E-03 8.65E-04 1.26E-04 NO DATA 3.84E-04 7.03E-03 1.06E-04 l
- Table taken from NUREG-0597.
1 1
l' l
1 l
l:
l i: -p V
TABLE 3.1-9 Rev. 28 L (1 of 1) 1/1/90
b h,
TABLE 3.1-10*
L -
(1 of 2)
- g. EXTERNAL DOSE FACTORS FOR STANDING ON CONTAMINATED GROUND-Il (mrem /hr per pC1/m8 )
Element' Total ~ Body Skin v
11 - 3 0.0 0.O Na-24 2.50E-08 2.90E-08' Cr 2.20E-10 2.60E-10 Mn-54 5.80E-09 6.80E-09 Mn-56 1.10E-08 1.30E-08' Fe-55 0.0 0.0:
Fe-59 8.00E-09 -
9.40E Co-58 7.00E-09 8.20E-09 Co-60 1.70E-08 2.00E-08 Ni-63 0.0 0.0, Ni-65 3.70E-09 4.30E-09 'l-Cu-64 1.50E-09 1.70E-09 Zn-65 4.00E-09 '4.60E-09
# Zn-69' .0.0 0,0 Br-83 6.40E-11 9.30E-11 .l
-Br-84 1.20E-08 1.40E-08 i
'Br-85 0.0. 0.0 i Rb-86 6.30E-10 7.20E-10 !
-Rb-88 3.50E-09 -4.00E-09 Rb-89 1.50E-08 1.80E-08 i
'Sr-89 5.60E-13 , 6.50E-13 Sr-91 7.10E-09 8.30E-09
/ Sr-92 9.00E-09 1.00E-08
~ y]/ Y-90 2.20E-12 2.60E-12 i Y-91M 3.80E-09 4.40E-09 !
Y 2.40E-11 2.70E Y-92 1.60E-09' 1.90E-09 Y-93 5.70E-10 7.80E-10 Zr-95 5.00E-09 5.80E-09 1 Zr-97 5.50E-09 6.40E-09 ll Nb-95 5.10E-09 6.00E 1 Mo-99 1.90E-09 2.20E i
-Tc-99M- 9.60E-10 1.10E-09 i Tc-101 2.70E-09 3.00E-09 j Ru-103 3.60E-09 4.20E ;
4.50E-09 5.10E-09 Ru-105 Ru-106 1.50E-09 1.80E-09 Ag-110M 1.80E-08 2.10E-08 l
~Te-125M 3.50E-11 4. 80E-11-- !
-Te-127M 1.10E-12 1.30E-12 Te-127 1.00E-11 1.10E-11 !
Te-129M 7.70E-10 9.00E-10 i Te-129 7.10E-10 8.40E-10 j
-*Taken from Regulatory Guide 1.109 (Rev. 1) i TABLE 3.1-10
[
M (1 of 2) ;
Revision 28 1/1/90
p i
TABLEL3.1-10 (ctnt d)
(2 of-2) '
_ . EXTERNAL DOSE FACTORS FOR STANDING ON CONTAMINATED GROUND
,rx .
i f (mrem /hr per pCi/m')
A._/
Element Total Body Skin Te-131H 8.40E 9.90E-09 Te-131- 2.20E-09 2.60E-06 .
Te-132 1.70E 2.00E-09 I-130 1.40E-08 1.70E-08 s
.I-131 2.80E-09 3.40E-09 I-132 1.70E-08 2.00E -t I-133- 3.70E-09 _4.50E-09 '
I-134 1.60E-08 1.90E-08 I-135 1.20E-08 1.40E-08 Cs-134 1.20E-08 1.40E-08 Cs-136' 1.50E-08 1.70E-08 Cs-137 4.20E-09 4.90E-09 Cs-138 2.10E-08 2.40E-08 .
f Ba-139 2.40E-09 2.70E-09 Ba-140 2.10E-09 2.40E-09 Ba-141 4.30E-09 4.90E-09 Ba-142 7.90E 9.00E-09 La-140 1.50E-08 1.70E-08 LLa-142 1.50E-08 1.80E-08 Ce-141 5.50E-10 6.20E-10 Ce-143 2.20E-09 2.50E-09 Ce-144' 3.20E-10 3.70E-10 L'
[ ') . Pr-143 0.0 0.0
\_ / Pr-144 2.00E-10 2.30E-10 Nd-147 1.00E-09 1.20E-09 W-187' 3.10E-09 '3.60E-09 Np-239 9.50E-10 1,10E-09 L
4 l
l Es TABLE 3.1-10 i
.( ) (2 of 2)
1 .
I. ,
i TABII 3.1-11* '
(1 of 1)
STABLE ELEMENT TRANSFER- DATA ,
h- ' B gy F,(Cow) Fg Element
- Ven/ Soil Milk (d/t) Meat (d/km)
H- 4.8E+00 1.0E-02** 1.2E Na 5.2E-02 4.0E-02 3.0E-02 '
Cr 2.5E-04 2.2E-03 2.4E-03 Mn 2.9E-02 2.5E-04 8.0E-04
- Fe 6.6E-04 1.2E-03** 4.0E-02 Co 9.4E-03 1.0E-03. 1.3E-02
/ - Ni 1.9E-02 6.7E-03 -5.3E-02 ,
Cu 1.2E-01 1.4E-02** 8.0E-03 Zn 4.0E-01 3.9E-02 3.0E-02 Rb 1.3E-01 3.0E-02 3.1E-02 Sr 1.7E-02 8.0E-04** 6.0E-04 -
Y 2.6E-03 1.0E-05 4.6E-03 Zr 1.7E-04 5.0E-06 3.4E-02 Nb 9.4E-03 2.5E-03 2.8E-01 '
Mo 1.2E 7.5E 8.0E-03
'Tc 2.5E-01 2.5E-02 4.0E-01 l
- Ru 5.0E-02 1.0E-06 4.0E-01 Rh' 1.3E+01 1.0E-02 1.5E-03 Ag 1.5E-01 5.0E-02 1.7E-02 To 1.3E+00 1.0E-03 7.7E-02 ,
I 2.0E 6.0E-03** 2.9E-03 tN Cs 1.0E-02 1.2E-02** 4.0E-03
' ( ,) Ba 5.0E-03 4.0E 3.2E-03 2.5E-03 La 5.0E-06 2.0E-04 Ce= 2.5E-03 1.0E-04 1.2E-03 Pr 2.5E-03 5.0E-06 4.7E-03 Nd 2.4E-03 5.0E-06 3.3E-03 W. 1.8E-02 5.0E-04 1.3E-03 Np 2.5E-03 5.0F-O' 2.0E-04 l
lw
- Taken'from Regulatory Guide 1.109 (Rev. 1) l **Nuclide Transfer parameters for Goat's milk l-l Element Fm (d/1)
H 0.17 L Fe 1.30E-04 l
[ Cu 0.013 Sr 0.014 I 0.06 Cs 0.30 )
l l
(% l (j
TABLE 3.1-11 Rev. 28 (1 of 1) 1/1/90 ,
1 l
._. . . _ _ _ _ ._-l
. . . . - . - . . . = _ . .
ih .
.]
n t ,-
- ? 't - TABLE 3.1-12 )
(M)- : (1 of 1)
RgVALUES - GROUND PATHWAY'- ALL AGES l
?
' NUCLIDE T. BODY -SKIN H -3 - NO DATA NO DATA g CR 511 4.65E+06 5.49E+06 '
MN 54 1.38E+09 1.62E+09 FE 55 : NO DATA NO DATA
, ; FE 59 2.72E+08 3.20E+08 C0 58 3.79E+08 4.44E+08 CO 60 2.15E+10- 2.53E+10' ZN 65 7.44E+08 8.56E+08 ;
SR 89 2.16E+04- 2.50E+04 SR 90- NO DATA NO DATA '
ZR'95 2.51E+08 2.91+08-MO 99 4.63E+06 4.00E+06 l SB.124- 5.98E+08 6.91E+08- -
I 131 8.59E+06' 1.04E+07
- I 133 1.22E+06 1.49E+06 I J" CS'134 .6.82E+09 7.96E+09-CS:136 l'. 50E+08 1.70E+08 CS'137 1.03E+10 1.20E+10 L . .
BA 140 2.05E+07 2.34E+07 l l-
-(N- CE-141, 1.36E+07 .1.54E+07 *
.J CE:144 6.92E+07 8.01E+07 E 'q,)? .
l' o
I l
l 1
1 l
l 1.
5 i
.p).
f -
TABLE 3.1-12 Rev. 28 (1 of 1). 1/1/90 4
rs TABLE 3.1-13 1
)- (1 of 1)
RgVALUES - VEGETABLE PATINAY - ADULT NUCLIDE' BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI H 3 0.0 2.28E+03 2.28E+03 2.28E+03 2.28E+03 2.28E+03 2.28E+03 i CR 51 0,0 0.0 4.58E+04 2.74E+04 1.01E+04 6.07E+04 1.15E+07 5
MN 54 0.0 3.07E+08 5.86E+07 0.0 9.14E+07 0.0 9.41E+08 FE 55 1.99E+08 1.38E+08 3.21E+07 0.0 0.0 7.68E+07 7.90E+07 FE 59 1.23E+08 2.90E+08 1.11E+08 0.0 0.0 8.09E+07 9.66E+0S CO 58 0.0 2.99E+07 6.71E407 0.0 0.0 0.0 6.07E+08 CO 60 0.0 1.66E+08 3.67E+08 0.0 0.0 0.0 3.12E+09 ZN 65 4.00E+08 1.27E+09 5.76E+08 0.0 8.52E+08 0.0 8.02E+08 SR 89 9.75E+09 0.0 2.80E+08 0.0 0.0 0.0 1.56E+09 SR 90 6.70E+11 0.0 1.64E+11 0.0 0.0 0.0 1.94E+10 ZR 95 1.16E+06 3.73E+05 2.52E+05 0.0 5.85E+05 .0. 0 1.18E+09 MO 99 0.0 6.20E+06 1.18E+06 0.0 1~.40E+07 0.0 1.44E+07 l SB 124 1.01E+08 1.91E+06 4.01E+07 2.45E+05 0.0 7.88E+07 2.87E+09 I 131 4.03E+07 5.76E+07 3.30E+07 1.89E+10 9.88E+07 0.0 1.52E+07 I 133 1.04E+06 1.80E+06 5.50E+05 2.65E+08 3.15E+06 0.0 1.62E+06 q-T ') CS-134 CS 136 4.54E+09- 1.08E+10 8.83E+09 4.23E+07 1.67E+08 '1.20E+08 0.0 0.0 3.~49E+09 1.16E+09 1.89E+08 9.30E+07 1.27E+07 1.90E+07 CS 137 6.63E+09 9.07E+09 5.94E+09 0.0 3.08E+09 1.02E+09 1.76E+08 BA 140- 1.28E+08 1.61E+05 8.40E+06 0.0 5.47E+04 9.22E+04 2.64E+08 CE 141 1.94E+05 1.31E+05 1.49E+04 0.0 6.09E+04 0.0 5.02E+08 CE 144- 3.15E+07 1.31E+07 1.69E+06 0.0 7.80E+06 0.0 1.06E+10 A
b TABLE 3.1-13 Rev. 28 (1 of 1) 1/1/90
)
p 1
('y TABLE 3.1-14 ,
( J' (1 of 1) 1 4
RgVALUES - VEGETABLE PATINAY - TEENAGER NUCLIDE BONE LIVER T. BODY TIIYROID KIDNEY LUNG GI-LLI ;
1 11 3 0.0 2.61E+03 2.61E+03 2.61E+03 2.61E+03 2.61E+03 2.61E+03 l CR 51 0.0 0.0 6.08E+04 3.38E+04 1.33E+04 8.68E+04 1.02E+07 i MN 54 0.0 4.46E+08 8.85E+07 0.0 1.33E+08 0.0 9.15E+08 FE 55 '3.10E+08 2.20E+08 5.13E+07 0.0 0.0 1.39E+08 9.51E+07 FE 59 1.75E+08 4.09E+08 1.58E+08 0.0 0.0 1.29E+08 9.68E+08
,t-CO 58 0.0 4.25E+07 9.79E+07 0.0 0.0 0.0 5.86E+08 CO 60 0.0 2.47E+08 5.57E+08 0.0 0.0 0.0 3.22E+09 ZN 65 5.35E+08 1.86E+09 8.66E+08 0.0 1.19E+09 0.0 7.86E+08 SR 89 1.48E+10 0.0 4.24E+08 0.0 0.0 0.0 1.76E+09 SR 90 8.32E+11 0.0 2.05E+11 0.0 0.0 0.0 2.34E+10 ZR 95 1.70E+06 5.38E+05 3.70E+05 0.0 7.90E+05 0.0 1.24E+09
- MO 99 0.0 5.69E+06 1.09E+06 0.0 1.30E+07 0.0 1.02E+07 l SB 124 1.51E+08 2.78E+06 5.88E+07 3.42E+05 0.0 1.32E+08 3.04E+09 I 131 3.83E+07 5.37E+07 2.88E+07 1.57E+10 9.24E+07 0.0 1.06E+07
'I 133 9.63E+05 1.63E+06 4.9CE+05 2.28E+08 2.87E+06 0.0 1.24E+06 rx
\ .V l
CS 134 CS 136 6.90E+09 1.62E+10 7.54E+09 4.33E+07 1.71E+08 1.15E+08 0.0 0.0 5.16E+09 1.97E+09 2.02E+08
-9.28E+07 1.46E+07 1.37E+07 CS 137 1.06E+10 -1.41E+10 4.90E+09 0.0 4.78E+09 1.86E+09 2.00E+08 BA 140 1.38E+08 1.69E+05 8.88E+06 0.0 5.72E+04 1.14E+05 2.12E+08 CE 141 2.78E+05 1.86E+05 2.13E+04 0.0 8.75E+04 0.0 5. 32E408 '
CE 144 5.04E+07 2.09E+07 2.71E+06 0.0 1.25E+07 0.0 1.27E+10
- l l-l l-l O 1 l .b w
TABLE 3.1-14 Rev. 28 l (1 of 1) 1/1/90 -l l
i I
1
/ N-- TABLE 3.1-15 Cli (1 of 1) >
RgVALUES'- VEGETABLE PAT}NAY - CHILD NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI H 3 0.0 4.04E+03 4.04E+03 4.04E+03 4.04E+03 4.04E+03 4.04E+03 CR 51 - 0. 0 0.0 1.15E+05 6.40E+04 1.75E+04 1.17E+05 6.12E+06 MN 54 0.0 6.53E+08 1.74E+08 0.0 1.83E+08 0.0 5.48E+08 FE.55 7.62E+08 4.04E+08 1.25E+08 0.0 0.0 2.29E+08 7.49E+07
-FE 59 3.88E+08 6.29E+08 3.13E+08 0.0 0.0 1.82E+08 6.54E+08 CO 58 0.0 6.27E+07 1.92E+08 0.0 0.0 0.0 3.66E+08 CO 60 0.0 3.76E+08 1.11E+09 0.0 0.0 0.0 2.08E+09 ZN 65 1.02E+09 2.73E+09 1.70E+09 0.0 1.72E+09 0.0 4.80E+08 SR 89 3.52E+10 0.0 1.00E+09 0.0 0.0 0.0 1.36E+09-SR 90 1.38E+12 0.0 3.49E+11 0.0 0.0 0.0 1.86E+10 ZR 95 3.82E+06 8.40E+05 7.48E+05 0.0 1.20E+06 0.0 8.77E+08 110 99 0.0 7.77E+06 1.92E+06 0.0 1.66E+07 0.0 6.43E+06 l SB 124 3.44E+08 4.46E+06 1.20E+08 7.59E+05 0.0 1.91E+08 2.15E+09 I 131 7.13E+07 7.17E+07 4.08E+07 2.37E+1C 1.18E+08 0.0 6.39E+06
-1 133 1.76E+06 2.17E+06 8.22E+05 4.03E+08 3.62E+06 0.0 8.75E+05 t
i
( ,)t '
CS 134 1.56E+10 2.56E+10 5.40E+09 0.0 7.93E+09 2.85E+09 1.38E+08 CS 136 8.16E+07 2.24E+08 1.45E+08 0.0 1.19E+08 1.78E+07 7.88E+06 CS 137 2.49E+10 2.39E+10 3.52E+09 0.0 7.78E+09 2.80E+09 1.50E+08 BA 140 2.76E+08 2.42E+05 1.61E+07- 0.0 7.87E+04 1.44E+05 1.40E+08 CE 141 6.45E+05 3.22E+05 4.78E+04 0.0 1.41E+05 0.0 '4.02E+08 CE 144 1 22E+08 3.81E+07 6.48E+06
. 0.0 2.11E+07 0.0 9.93E+09 1
l-l l
l 1
(
f, TABLE 3.1-15 Rev. 28 (1 of 1) 1/1/90 l l
t k TABLE 3.1-16
() (1 of 1)
RgVALUES - MEAT PATHWAY - ADULT J
NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI H 3 0.0 3.27E402 3.27E+02 3.27E+02 3.27E+02 3.27E+02 '3.27E+02 '
CR-51 0.0 0.0 5.86E+03 3.50E+03 1.29E+03 7.77E+03 1.47E+06 MN 54 0.0 6.83E+06 1.30E+06 0.0 2.03E+06 0.0 2.09E+07 FE 55 2.13E+08 1.47E+08 3.43E+07 0.0 0.0 8.20E+07 8.44E+07-FE 59 2.12E+0B 4.99E+08 1.91E+08 0.0 0.0 1.39E+08 1.66E+09 CO 58 0.0 1.41E+07 3.17E+07 0.0 0.0 0.0 2.87E+08 CO 60 0.0 5.56E+07 1.23E+08 0.0 0.0 0.0 1.04E+09 ZN 65 3.01E+08- 9.57E+08 4.32E+08 0.0 6.40E+08 0.0 6.03E+08
'SR 89 2.39E+08 0.0 6.86E+06 0.0 0.0 0.0 3.83E+07 SR 90 9.67E+09 0.0 2.37E+09 0.0 0.0 0.0 2.79E+08 ZR 95 1.47E+06 4.72E+05 3.20E+05 0.0 7.41E+05 0.0 1.50E+09 MO 99 0.0 9.38E+04 1.78E+04 0.0 2.12E+05 0.0 2.17E+05 l SB 124 1.55E+07 2.93E+05 6.15E+06 3.76E+04 0.0 1.21E+07 4.40E+08 I 131 4.92E+06 7.03E+06 4.03E+06 2.30E+09 1.21E+07 0.0 1.86E+06 I 133 1.69E-01 2.94E-01 8.97E-02 4.32E+01 5.14E-01 0.0 2.65E-01 1
\_-) CS 134 4.83E+08 1.15E+09 9.39E+08- 0.0 3.72E+08 1.23E+08 2.01E+07 CS 136 1.06E+07 4.20E+07 3.03E+07 0.0 2.34E+07~ 3.21E+06 4.78E+06 CS 137 6.58E+08 9.00E+08 5.89E+08 0.0 3.05E+08 1.02E+0B 1.74E+07 BA 140 2.56E+07 3.22E+04 1.68E+06 0.0 1.09E+04 1.84E+04 5.27E+07 CE 141 1.15E+04 7.79E+03 8.84E+02 0.0 3.62E+03 0.0 2.98E+07 CE 144 1.07E+06 4.49E+05 5.76E+04- 0.0 2.66E+05 0.0 3.63E+08 I
i TABLE 3.1-16 Rev. 28 (1 of 1) 1/1/90 l
e
-(\ TABLI 3.1-17 (1 of 1)
- (~'/ .
RgVALUES - MEAT PATHWAY - TEENAGER NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI H 3 0.0 1.95E+02 1.95E+02 1.95E+02 1.95E+02 1.95E+02 1.95E+02 CR 51 0.0 0.0 4.68E+03 2.60E+03 1.03E+03 6.69E+03 7.87E+05 4
MN 54 0.0 5.21E+06 1.03E+06 0.0 1.55E+06 0.0 1.07E+07 FE 55 1.73E408 1.23E+08 2.86E+07 0.0 0.0 7.78E+07 5.31E+07 FE 59 1.70E+08 3.96E+08 1.53E+06 0.0 0.0 1.25E+08 9.36E+08' CO 58 0.0 1.09E+07 2.51E+07 0.0 0.0 0.0' 1.50E+08 1 CO 60 0.0 4.31E+07 9.72E+07 0.0 0.0 0.0 5.62E+08 i ZN 65 2.11E+08 7.34E+08 3.43E+08 0.0 4.70E+08 0.0 3.11E+08 '
l SR 89 2.02E+08 0.0 5.78E+06 0.0 0.0 0.0 2.40E+07 SR 90 6.26E+09 0.0 1.55E+09 0.0 0.0 0.0 1.76E+08 ZR 95 1.18E+06 3.72E+05 2.56E+05 0.0 5.47E+05 0.0 8.58E+08 MO 99 0.0 7.75E+04 1.48E+04 0.0 l'.77E+05 0.0 1.39E+05 l SB 124 1.27E+07 2.33E+05 4.94E+06 2.87E+04 0.0 1.11E+07 2.55E+08 I 131 4.09E+06- 5.72E+06 3.07E+06 -1.67E+09 9.85E+06 0.0 1.13E+06 I 133 1.42E-01 2.40E-01 7.32E-02 3.35E+01 4.21E-01 0.0 1.82E-01
\ _) CS~134 .3.84E+08 9.04E+08 4.19E+08 0.0 2.87E+08 1.10E+08 1.12E+07
=CS 136 8.30E+06 .3.27E+07 2.19E+07 0.0 1.78E+07 2.80E+06 2.63E+06 CS 137- 5.46E+08 7.27E+08 2.53E+08 0.0 2.47E+08 9.61E+07 1.03E+07 BA 140 2.12E+07 2.59E+04 1.36E+06 0.0 8.79E+03 1.74E+04 3.26E+07 CE 141 9.67E+03 6.46E+03 7.42E+02 0.0 3.04E+03 0.0 1.85E+07 CE 144- 9.04E+05 3.74E+05 4.86E+04 0.0 2.24E+05 0.0 2.27E+08 l
l I /~'T l I_l s
L TABLE 3.1-17 Rev. 28 (1 of 1) 1/1/90
P 7
t
<"'s TABLE 3.1-18 Li
)- (1 of 1)
RgVALUES - MEAT PATHWAY - CHILD NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI H 3 0.0 2.36E+02 2.36E+02 2.36E+02 2.36E+02 2.36E+02 2.36E+02 CR 51 0.0 0.0 7.31E+03 4.06E+03 1.11E+03 7.40E+03 3.87E+05 MN 54 0.0 5.96E+06 1.59E+06 0.0 1.67E+06 0.0 5.00E+06 FE 55 3.32E+08 1.76E+08 5.45E+07 0.0 0.0 9.95E+07 3.26E+07 FE 59 3.01E+08 4.86E+08 2.42E+08 0.0 0.0 1.41E+08 5.06E+08
-CO 58 0.0 1.27E+07 3.90E+07 0.0 . 0. 0 0.0 7.43E+07 CO 60 0.0 5.12E+07 1.51E+08 0.0 0.0 0.0 2.84E+08 ZN 65 3.17E+08 8.45E+08 5.26E+08 0.0 5.33E+08- 0.0 1.48E+08 SR 89 3.82E+08 0.0 1.09E+07 0.0 0.0 0.0 1.48E+07 SR 90 8.08E+09 0.0 2.05E+09 0.0 0.0 0.0 1.09E+08 ZR 95 2.09E+06 4.60E+05 4.10E+05 0.0 6.59E+05 0.0 4.80E+08 MO 99 0.0 1.08E+05 2.67E+04 0.0 2.?0E+05 0.0 8.92E+04 l SB 124 2.29E+07 2.97E+05 8.03E+06 5.06E+04 0.0 1.27E+07 1.43E+08 I 131 7.58E+06 7.62E+06 4.33E+06 2.52E+09 1.25E+07 0.0 6.78E+05 I 133 2.63E-01 3.25E-01 1.23E-01 6.04E+01 5.42E-01 0.0 1.31E-01 O
('~,/ L CS 134 6.77E+08 .1.11E+09 2.34E+08 0.0 3.44E+08 1.24E+08 5.99E+06 CS 136 1.43E+07 3.94E+07 2.55E+07 0.0 2.10E+07 .3.13E+06 1.38E+06 CS 137 1.01E+09 9.63E+08 1.42E+08 0.0 3.14E+08 1.13E+08 6.03E+06 BA 140 3.91E+07 .3.42E+04 2.28E+06 0.0 1.11E+04 2.04E+04 1.98E+07 CE 141 1.82E+04 9.08E+03 1.35E+03 0.0 3.58E+03 0.0- 1.13E+07 CE 144 1.70E+06 5.34E+05 9.10E+04 0.0 2.96E+05 0.0 1.39E+08
(- / l TABLE 3.1-18 Rev. 28 (1 of 1) 1/1/90 l l
I 1
N
('w4 TABLE 3.1-19
.('~j '
('1 of 1)
Rg_ VALUES - COW HILK PATHWAY - ADULT ,
NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI H 3 0.0 7.69E+02 7.69E+02 7.69E+02 7.69E+02 7.69E+02 7.69E+02 CR 51 0.0 0.0 2.38E+04 1.42E+04 5.24E+03 3.15E+04 5.98E+06 MN 54 0.0 6.26E+06 1.19E+06 0.0 1.86E+06 0.0 1.92E+07 FE 55 1.82E+07 1.26E+07 2.94E+06 0.0 0.0 7.03E+06 7.22E+06 FE 59 2.37E+07 5.58E+07 2.14E+07 0.0 0.0 1.56E+07 1.86E+08 CO 58 0.0 3.66E+06 8.19E+06 0.0 0.0 0.0 7.41E+07 CO 60 0.0 1.21E+07 2.68E+07 0.0 0.0 0.0 2.28E+08 ZN 65 1.16E+09 3.69E+09 1.67E+09 0.0 2.47E+09 0.0 2.32E+09 SR 89 1.15E+09 0.0 3.30E+07 0.0 0.0 0.0 1.84E+08 SR 90 3.64E+10 0.0 8.93E+09 0.0 0.0 0.0 1.05E+09 ZR 95 7.38E+02 2.37E+02 1.60E+02 0.0 3.71E+02 0.0 7.50E+05 MO 99 0.0 2.32E+07 4.42E+06 0.0' 5.2SE+07 0.0 5.38E+07 l SB 124 2.02E+07 3.81E+05 7.99E+06 4.89E+04 0.0 1.57E+07 5.72E+08 I 131 1.36E+08 1.94E+08 1.11E+08 6.36E+10 3.32E+08 0.0 5.12E+07 I 133 1.80E+06 3.13E+06 9.55E+05 4.61E+08 5.47E+06 0.0 2.82E+06 13
$ ,), CS 134 4.15E+09 9.88E+09 8.08E+09- 0.0 3.20E+09 1.06E+09 1.73E+08 CS 136 2.33E+08 9.22E+08 6.63E+08 0.0 5.13E+08 7.03E+07 1.05E+08 CS 137 5.57E+09 7.62E+09 4.99E+09 0.0 2.59E+09 8.59E+08 1.47E+08 BA 140 2.39E+07 3.01E+04 1.57E+06 0.0 1.02E+04 1.72E+04 4.93E+07 CE 141 3.99E+03 2.70E+03 3.06E+02 0.0 1.25E+03 0.0 1.03E+07 CE 144 2.64E+05 1.10E+05 1.42E+04 0.0 6.55E+04 0.0 8.93E+07 L
l l
1 l
. (/'}
x- TABLE 3.1-19 (1 of 1) i Rev. 28 1/1/90 1
v.
t
}
l
/).
(jf TABLE 3.1-20 (1 of 1) i 1
R VALUES - COW MILK PATHWAY - TEENAGER I 3
NUCLIDE BONE LIVER T. BODY- THYROID KIDNEY LUNG GI-LLI 11 3 0.0 1.00E+03 1.00E+03 1.00E+03 1.00E+03 1.00E+03 1.00E+03 CR 51 0.0 0.0 4.15E+04 2.31E+04. 9.10E+03 5.93E+04 6.98E+06 MN 54 0.0 1.04E+07 2.07E+06 0.0 3.11E+06 0.0 2.14E+07 FE 55 3.23E+07 2.29E+07 5.34E+06 0.0 0.0 1.45E+07 9.92E+06 FE 59 4.14E+07 9.67E+07 3.73E+07 0.0 0.0 3.05E+07 2.29E+08 ,
CO 58 0.0 6.15E+06 1.42E+07 0.0 0.0 0.0 8.48E+07 CO 60 0.0 2.06E+07 4.63E+07 0.0 0.0 0.0 2.68E+08 ZN 65 1.78E+09 6.18E+09 2.88E+09 0.0 3.96E+09 0.0 2.62E+09 SR 89 2.12E+09 0.0 6.07E+07 0.0 0.0 0.0 2.53E+08 SR 90 5.14E+10 0.0 1.27E+10 0.0 0.0 0.0 1.44E+09 ZR 95 1.29E+03 4.07E+02 2.80E+02 0.0 5.98E+02 0.0 9.39E+05 MO 99 0.0 4.19E+07 7.99E+06 0.0 9.59E+07 0.0 7.50E+07 l SB 124 3.60E+07 6.62E+05 1.40E+07 8.16E+04 0.0 3.14E+07 7.25E+08 I 131 2.46E+0B 3.44E+08 1.85E+08 1.01E+11 5.93E+08 0.0 6.81E+07 I 133 3.29E+06 5.58E+06 1.70E+06 7.79E+08 9.79E+06 0.0 4.22E+06 y% . -
- 'N_,/ CS 134 '7.21E+09 1.70E+10 7.87E+09 0.0 5.39E+09 2.06E+09 2.11E+08 ,
CS 136 3.97E+08 1.56E+09 1.05E+09 0.0 8.51E+08 1.34E+08 1.26E+08 CS 137 1.01E+10 1.34E+10 4.68E+09 0.0 4.57E+09 1.78E+09 1.91E+08 BA 140 4.32E+07 5.30E+04 2.78E+06 0.0 1.80E+04 3.56E+04 6.67E+07 CE 141 7.31E+03 4.88E+03 5.61E+02 0.0 2.30E+03 0.0 1.40E+07 CE 144 4.86E+05 2.01E+05 2.61E+04 0.0 1.20E+05 0.0 1.22E+08 l
~
1
' '\-[\ TABLE 3.1-20 (1 of 1)
Rev. 28 1/1/90 l
l
6 j'^ , TABLE 3.1-21 0 .
(1 of 1)
RgVALUES - COW MILK PATHWAY - CHILD 1
NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI H 3 0.0 1.58E+03 1.58E+03 1.58E+03 1.58E+03 1.58E+03- 1.58E+03 CR 51- 0.0 0.0 0.47E+04 4.70E+04 1.28E+04 8.58E+04 4.49E+06 MN 34 0.0 1.56E+07 4.16E+06 0.0 4.38E+06 0.0 1.31E+07 FE 55 8.11E+07 4.30E+07 1.33E+07 0.0 0.0 2.43E+07 7.97E+06 FE 59 9.61E+07 1.55E+08 7.74E+07 0.0 0.0 4.51E+07 1.62E+08 CO 58 0.0 9.40E+06 2.88E+07 0.0 0.0 0.0 5.48E+07 CO 60 0.0 3.19E+07 9.41E+07 0.0 0.0 0.0 1.77E+08 ZN 65 3.49E+09 9.31E+09 5.79E+09 0.0 5.87E+09 0.0 1.63E+09 SR 89 5.25E+09 0.0 1.50E+08 0.0 0.0 0.0 2.03E+08 i SR 90 8.69E+10 0.0 2.20E+10 0.0 0.0 0.0 1.17E+09 ZR 95 3.00E+03 6.59E+02 5.86E+02 0.0 9.43E+02 0.0 6.87E+05 MO 99 0.0 7.62E+07 1.89E+07 0.0 1.63E+08 0.0 6.30E+07 l SB 124 8.51E+07 1.10E+06 2.98E+07 1.88E+05 0.0 4.72E+07 5.32E+08 I 131 5.97E+08 6.00E+08 3.41E+08 1.98E+11 9.85E+08 0.0 5.34E+07 I 133 8.00E+06 9.89E+06 3.74E+06 1.84E+09 1.65E+07 0.0 3.98E+06 C': '
k_,)
s CS 134 1.66E+10 2.73E+10 5.75E+09 0.0 8.45E+09 3.03E+09 1.47E+08-CS 136 8.97E+08 2.47E+09 1.60E+09 0.0 1.31E+09 1.96E+08 8.67E+07 CS 137 2.43E+10 2.33E+10 3.44E+09 0.0 7.59E+09 2.73E+09 1.46E+08 BA 140 1.04E+08- 9.14E+04 6.09E+06 0.0 2.98E+04 5.45E+04 5.29E+07 CE 141 1.80E+04 8.98E+03 1.33E+03 0.0 3.94E+03 0.0 1.12E+07 +
CE 144 1.20E+06 3.76E+05 6.40E+04 0.0 2.08E+05- 0.0 9.80E+07
[\ TABLE 3.1-21 (1 of 1)
Rev. 28 1/1/90 w
h tN TABLE 3.1-22
~'
I (1 of 1)
RgVALUES - COW MILK PATHWAY - INFANT NUCLIDE BONE LIVER T. BODY THYROID- KIDNEY LUNG GI-LLI H 3- 0.0 2.40E+03 2.40E+03 2.40E+03 2.40E+03 2.40E+03 2.40E+03 CR 51 0.0 0.0 1.34E+05 8.75E+04 1.91E+04 1.70E+05 3.91E+06 MN 54 0.0 2.90E+07 6.58E+06 0.0 6.43E+06 0.0 1.07E+07 FE 55 9.81E+07 6.34E+07- 1.69E+07 0.0 0.0 3.10E+07 8.04E+06 FE 59 1.79E+08 3.13E+08 1.23E+08 0.0 0.0 9.26E+07 1.50E+08 C0 58 0.0 1.88E+07 4.69E+07 0.0 0.0 0.0 4.69E+07 CO 60 0.0 6.52E+07 1.54E+08 0.0 0.0 0.0 1.55E+08 ZN 65 4.69E+09 1.61E+10 7.42E+09 0.0 7.80E+09 0.0 1.36E+10 SR-89 9.98E+09 0.0 2.86E+08 0.0 0.0 0.0 2.05E+08 SR 90 9.45E+10 0.0 2.41E+10 0.0 0.0 0.0 1.18E+09 ZR 95 5.32E+03 1.30E+03 9.20E+02 0.0 1.40E+03 0.0 6.46E+05 MO 99 0.0 1.95E+08 2.08E+07 0.0 2.91E+08 0.0 6.42E+07 l SB 124 1.64E+08 2.41E+06 5.08E+07 4.35E+05 0.0 1.03E+08 5.06E+08 I 131 1.25E+09 1.47E+09 6.45E+08 4.82E+11 1.71E+09 0.0 5.24E+07
!I 133 1.69E+07 2.46E+07 7.20E+06 4.47E+09 2.89E+07 0.0 4.16E+06 stN ,
dq,,) CS 134 '2.68E+10 4.99E+10 5.04E+09 0.0 1.29E+10 5.27E+09 1.36E+08 CS'136 1.75E+09 5.15E+09- 1.92E+09 0.0 2.05E+09 -4.20E+08 7.83E+07 CS 137 3.88E+10 4.54E+10 3.22E+09 0.0 1.22E+10 4.94E+09 1.42E+08 BA 140 2.15E+08 2.15E+05 1.11E+07 0.0 5.10E+04 1.32E+05 5.27E+07 CE 141 3.57E+04 2.18E+04 2.56E+03 0.0 6.71E+03 0.0 1.12E+07 CE 144 1.72Et06 7.03E+05 9.62E+04 0.0 2.84E+05 0.0 9.85E+07
/-
I TABLE 3.1-22 (1 of 1)
Rev. 28 1/1/90
4
.,s TABLE 3.1-23 "
(1 of 1)
RgVALUES - GOAT MILK PATHWAY - ADULT NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI H 3 0.0 1.57E+03 1.57E+03 1.57E+03 1.57E+03 1.57E+03 1.57E+03 CR 51 - 0. 0 0.0 2.85E+03 1.71E+03 6.28E+02 3.79E+03 7.17E+05
=MN 54 0.0 7.51E+05 1.43E+05 0.0 2.24E+05 0.0 2.30E+06 FE 55 2.37E+06 1.64E+06 3.82E+05 0.0 0.0 9.13E+05 9.39E+05 FE 59 3.09E+06 7.25E+06 2.78E+06 0.0 0.0 2.03E+06 2.42E+07 CO 58 0.0 4.39E+05 9.83E+05 0.0 0.0 0.0 8.89E+06 CO 60 0.0 1.46E+06 3.21E+06 0.0 0.0 0.0 2.73E+07 ZN 65 1.39E+08 4.43E+08 2.00E+08 0.0 2.96E+08 0.0 2.79E+08 SR 89 2.42E+09 0.0 6.93E+07 0.0 0.0 0.0 3.87E+08 SR 90 7.64E+10 0.0 1.87E+10 0.0 0.0 0.0 2.21E+09 ZR 95 8.85E+01 2.84E+01 1.92E+01 0.0 4.46E+01 0.0 9.00E+04 MO 99 0.0 2.78E+06 5.30E+05 0.0 6.31E+06 0.0 6.45E+06 l SB 124 2.42E+06 4.57E+04 9.59E+05 5.87E+03 0.0 1.8BE+06 6.87E+07 I 131 1.63E+08 2.33E+08 1.33E+08 7.63E+10 3.99E+08 0.0 6.14E+07 I 133 2.16E+06 3.76E+06 1.15E+06 5.53E+08 6.56E+06 0.0 3.38E+06 p- .
1 ,/
CS 134 1.25E+10 2.96E+10 2.42E+10 0.0 9.59E+09 3.18E+09 5.19E+08 CS-136 .7.00E+08 2.76E+09 1.99E+09- 0.0. 1.54E+09 2.11E+08 3.14E+08 CS 137 1.67E+10 2.28E+10 1.50E+10 0.0 7.76E+09 2.58E+09 4.42E+08 BA 140 2.87E+06 3.61E+03 1.88E+05 0.0 1.23E+03 2.07E+03 5.92E+06 CE 141 4.79E+02 3.24E+02 3.67E+01 0.0 1.50E+02 0.0 1.24E+06 CE 144 3.17E+04 1.33E+04 1.70E+03 0.0 7.86E+03 0.0 1.07E+07
(\
w/
) TABLE 3.1-23 (1 of 1)
Rev. 28 1/1/90
I l
l
. ,7~st TABLE 3.1-24 Q- (1 of 1)
RgVALUES - GOAT MILK PATHWAY - TEENAGER l
l NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI )
i
-H. 3 0.0' 204E+03 2.04E+03 2.04E+03 2.04E+03 2.04E+03 2.04E+03 CR 51 0.0 0.0 4.98E+03 2.77E+03 1.09E+03 7.11E+03 8.37E+05 MN 54 0.0 1.25E+06 2.48E+05 0.0 3.73E+05 0.0 2.57E+06 FE 55 4.20E+06 2.98E+06 6.95E+05 0.0 0.0 1.89E+06 1.29E+06 FE 59 5.39E+06 1.26E+07 4.85E+06 0.0 0.0 3.96E+06 2.97E+07 C0 58 0.0 7.39E+05 1.70E+06 0.0 0.0 0.0 1.02E+07-CO 60 0.0 2.47E+06 5.56E+06 0,0 0.0 0.0 3.21E+07 ZN 65 2.14E+08 7.42E+08 3.46E+08 0.0 4.75E+08 0.0 3.14E+08 SR 89 4.45E+09 0.0 1.28E+08 0.0 0.0 0.0 5.30E+08 SR 90 1.08E+11 0.0 2.67E+10 0.0 0.0 0.0 3.03E+09 ZR 95 1.55E+02 4.88E+01 3.36E+01 0.0 7.18E+01 0.0 1.13E+05 MO 99 0.0 5.03E+06 9.59E+05 0.0 1.15E+07 0.0 9.00E+06 l i SB 124- 4.31E+06 7.95E+04 1.68E+06 9.79E+03 0.0 3.77E+06 8.70E+07 I 131 2.95E+08 4.13E+08 2.22E+08 1.21E+11 7.12E+08 0.0 8.18E+07 I 133 3.95E+06 6.70E+06 2.04E+06 9.35E+08 1.17E+07 0.0 5.07E+06 p);
(_, '
CS 134 2.16E+10 5.09E+10 2.36E+10 0.0 1.62E+10 6.17E+09 6.33E+08 CS 136 1.19E+09 4.69E+09 3.15E+09 0.0 2.55E+09 4.03E+08 3.78E+08 CS 137 3.03E+10 4.03E+10 1.40E+10 0.0 1.37E+10 5.33E+09 5.73E+08 BA 140 5.19E+06 6.35E+03 3.34E+05 0.0 2.15E+03 4.27E+03 8.00E+06 CE 141 8.77E+02 5.86E+02 6.73E+01 0.0 2.76E+02 0.0 1.68E+06 CE 144~ 5.83E+04 2.41E+04 3.14E+03 0.0 1.44E+04 0.0 1.47E+07 L
l /"
L f TABLE 3.1-24
. (1 of 1)
Rev. 28 1/1/90
U A. TABLE 3.1-25.
i
\
(1 of 1)
RgVALUES - GOAT MILK PATHWAY - CHILD
'NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI H 3 0.0 3.23E+03 3.23E+03 3.23E+03 3.23E+03 3.23E+03 3.23E+03 CR 51 0.0 0.0 1.02E+04 5.64E+03 1.54E+03 1.03E+04 5.39E+05 MN 54 0.0 1.87E+06 4.99E+05 0.0 5.25E+05 0.0 1.57E+06 ,
FE 55- 1.05E+07 5.59E+06 1.73E+06 0.0 0.0- 3.16E+06 1.04E+06 l FE 59 1.25E+07 2.02E+07 1.01E+07 0,0 0.0 5.86E+06 2.10E+07 I CO 58 0.0 1.13E+06 3.45E+06 0.0 0.0 0.0 6.58E+06 CO 60 0.0 3.83E+06 1.13E+07 0.O ~0,0 0.0 2.12E+07 -l ZN 65 4.19E+08 1.12E+09 6.95E+08 0.0 7.04E+08 0.0 1.96E+08 SR 89 1.10E+10 0.0 3.15E+08 0.0 0.0 0.0 4.27E+08 ;
SR 90 1.82E+11 0.0 4.62E+10 0.0 0.0 0.0 2.46E+09 ZR 95 3.60E+02 7.91E+01 7.04E+01 0.0 1.13E+02 0.0 8.25E+04 ;
MO 99 0.0 9.15E+06 2.26E+06 0.0 1.95E+07 0.0 7.57E+06 1 !
l SB 124 1.02E+07 1.32E+05 3.58E+06 2.25E+04 0.0 5.67E+06 6.38E+07 i I 131 7.16E+08 7.20E+08 4.09E+08 2.38E+11 1.18E+09 0.0 6.41E+07 I 133 9.59E+06 1.19E+07 4.49E+06 2.20E+09 1.98E+07 0.0 4.78E+06 l i
4.99E+10 '8.18E+10 1.73E+10 2.69E+09 7.40E+09 4.79E+09 0.0 0.0 2.54E+10 9.10E+09 4.41E+08 3.94E+09 5.88E+08 2.60E+08.
CS'137 7.30E+10 6.98E+10 1.03E+10 0.0 2.28E+10 8.19E+09 4.37E+08 i
BA 140 1.25E+07 1.10E+04 7.31E+05 0.0 3.57E+03 6.54E+03 6.34E+06 CE 141 2.16E+03 1.08E+03 1.60E+02 0.0 4.72E+02 0.0 1.34E+06 CE 144 1.44E+05 4.51E+04 7.68E+03 0.0 2.50E+04 0.0 1.18E+07 3
l
]
.3
[ TABLE 3.1-25
\ (1 of 1) )
Rev. 28 1/1/90
- - _ - _ _ . . _ A
7 TABLE 3.1-26 d[O !
(1 of 1)
RgVALUES - GOAT MILK PATHWAY - INFANT NUCLIDE BONE- LIVER T. BODY THYROID KIDNEY LUNG GI-LLI H 3 0.0 4.90E+03 4.90E+03 4.90E+03 4.90E+03 4.90E+03 4.90E+03 CR 51 0.0 0.0 1.61E+04 1.05E+04 2.29E+03 2.04E+04 4.69E+05 MN 54 0.0 3.48E+06 7.89E+05 0.0 7.72E+05 0.0 1.28E+06 FE 55 1.27E+07 8.24E+06 2.20E+06- 0.0 0.0 4.03E+06 1.05E+06 FE 59 2.33E+07 4.07E+07 1.60E+07 0.0 0.0 1.20E+07 1.95E+07 CO 58 0.0 2.26E+06 5.63E+06 0.0 0.0 0.0 5.62E+06 i CO 60 0.0 7.82E+06 1.85E+07 0.0 0.0 0.0 1.86E+07 !
ZN 65 5.63E+08 1.93E+09 8.91E+08 0.0 9.36E+08 0.0 1.63E+09 !
1 1
SR 89 2.10E+10 0.0 6.01E+08 0.0 0.0 0.0 4.31E+08 SR 90 1.98E+11 0.0 5.05E+10 0.0 0.0 0.0 2.48E+09 ZR 95 6.39E+02 1.56E+02 1.10E+02 0.0 1.68E+02 0.0 7.75E+04 MO 99- 0.0 2.34E+07 4.56E+06 0.0 3.49E+07 0.0 7.70E+06 l f SB 124 -1.97E+07 2.90E+05 6.10E+06 5.22E+04 0.0 1.23E+07 6.07E+07 1 I 131 1.49E+09 1.76E+09 7.74E+08 5.79E+11 2.06E+09 0.0 6.29E+07 )
I 133 2.03E+07 2.95E+07 8.64E+06 5.36E+09 3.47E+07 0.0 4.99E+06 i rN i i
s ,)
s CS 134 8.03E+10 1.50E+11 1.51E+10 0.0 3.86E+10 1.58E+10 4.07E+08 l CS 136 5.26E+09 1.55E+10 5.77E+09 0.0 6.16E+09 1.26E+09 2.35E+08 '
CS 137 1.16E+11 1.36E+11 9.66E+09 0.0 3.66E+10 1.48E+10 4.26E+08 l BA 140 2.58E+07 2.58E+04 1.33E+06 0.0 6.12E+03 1.58E+04 6.33E+06 i CE 141 4.28E+03 2.61E+03 3.07E+02 0.0 8.05E+02 0.0 1.35E+06 l CE 144 2.06E+05 8.44E+04 1.15E+04 0.0 -3.41E+04 0.0 1.18E+07 I
1
\
TABLE 3.1-26 (1 of 1)
Rev. 28 1/1/90 w
M i
i f) TABLE 3.1-27 1
-t / (1 of 1)
Rg_VA M S - INHA W ION PA M AY - N NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI H 3 0.0 1.26E+03 1.26E+03 1. M +03 1.26E+03 1.26E+03 1.26E+03 j
.CR 51 0.0 0.0 9.99E+01 5.94E+01 2.28E+01 5.94E+04 3.32E+03 MN 54 0.0 3.95E+04 6.29E+03 0.0 9.83E+03 1.40E+06 7.72E+04 FE 55 2.45E+04 1.69E+04 3.94E+03 0.0 0.0 7.20E+04 6.02E+03 ;
FE 59 1,17E+04 2.77E+04 1.05E+04 0.0 0.0 1.01E+06 1.88E+05 l
, CO 58 0.0 1.58E+03 2.07E+03 0.0 0.0 9.27E+05 1.06E+05 CO 60 0.0 1.15E+04 1.48E+04 0.0 0.0 5.96E+06 2.84E+05 l ZN 65 3.24E+04 1.03E+05 4.65E+04 0.0 6.89E+04 8.63E+05. 5.34E+04 l
.1 SR 89 3.04E+05 0.0 8.71E+03 0.0 0.0 1.40E+06 3.49E+05 ;
SR 90 9.91E+07 0.0 6.09E+06 0.0 0.0 9.59E+06 7.21E+05 l ZR 95 1.07E+05 3.44E+04 2.32E+04 0.0 5.41E+04 1.77E+06- 1.50E+05 l MO 99 0.0 1.21E+02 2.30E+01 0.0 2.92E+02 9.13E+04' 2.48E+05 l l l
SB 124 3.12E+04 5.88E+02 1.24E+04 7.54E+01 0.0 2.48E+06 4.06E+05 l I 131 2.52E+04 3.57E+04 2.05E+04 1.19E+07 6.12E+04 0.0 6.27E+03 I 133 8.63E+03 1.48E+04 4.51E+03 2.15E+06 2.58E+04 0.0 8.87E+03 CS 134 '3.72E+05 8.47E+05 7.27E+05 0.0 2.87E+05 9.75E+04 1.04E+04 CS 136 3.90E+04 1.46E+05 1.10E+05 0.0 8.55E+04 1.20E+04 1.17E+04 '
CS 137 4'.78E+05 6.20E+05 4.27E+05 0.0 2.22E+05 7.51E+04 8.39E+03 BA 140 3.90E+04 4.90E+01 2.56E+03 0.0 1.67E+01 1.27E+06 2.18E+05' i CE 141 1.99E+04 1.35E+04 1.53E+03 0.0 6.25E+03 3. 61E+(,5 - 1.20E+05 -l CE 144 3.43E+06 1.43E+06 1.84E+05 0.0 8.47E+05 7.76E+06 8.15E+05 i
I l
1 l
l l
l l
l TABLE 3.1-27 j (1 of 1) '
l Rev. 28 1/1/90
p
- ~
l i/~' -
'TABIZ 3.1-28 1 (1 of 1)
Rg VA M S - INHA W ION PA M AY - EENAGER NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI
.H 3 0.0 1.27E+03 1.27E+03 1.27E+03 1.27E+03 1.27E+03 1.27E+03 CR 51 ' O.0 0.0 -1.35E+02 7.49E+01 3.07E+01 2.09E+04 3.00E+03 1
MN 54 0.0 5.10E+04 8.39E+03 0.0 1.27E+04 1.98E+06 6.67E+04 FE 55 3.34E+04 2.38E+04 5.54E+03 0.0 0.0 1.24E+05 6.38E+03 FE 59 1.59E+04 3.69E+04 1.43E+04 0.0 0.0 1.53E+06 1.78E+05 -
l CO 58 0.0 2.07E+03 2.77E+03 0.0 0.0 1.34E+06 9.51E+04 CO 60 0.0 1.51E+04 1.98E+04 0.0 0.0 8.71E+06 2.59E+05 ZN 65 3.85E+04 1.33E+05 6.23E+04 0.0 8.63E+04 1.24E+06 4.66E+04 SR 89 4.34E+05 0.0 1.25E+04 0.0 0.0 2.41E+06 3.71E+05 SR 90 1.08E+08 0.0 6.67E+06 0.0 0.0 1.65E+07 7.64E+05 ZR 95 1.45E+05 4.58E+04 3.15E+04 0.0 6.73E+04 2.6BE+06 1.49E+05 MO 99 0.0 1.69E+02 3.23E+01 0.0' 4.12E+02 1.54E+05- 2.69E+05 l SB 124 4.30E+04 7.92E+02 1.68E+04 9.75E+01 0.0 3.84E+06 3.98E+05 I 131 3.54E+04 4.90E+04 2.64E+04 1.46E+07 8.39E+04 0.0 6.48E+03 I 133 1.21E+04 2.05E+04 6.21E+03 2.92E+06 3.59E+04 0.0 1.03E+04
,(m
%s jr CS 134 5.02E+05 1.13E+06 5.48E+05 0.0 3.75E+05 1.46E+05 9.75E+03 '
CS 136 5.14E+04 1.93E+05 1.37E+05 0.0 1.10E+05 1.77E+04 1.09E+04 CS 137 6.69E+05 8.47E+05 3.11E+05 0.0 3.04E+05 1.21E+05 8.47E+03 BA 140 5.46E+04 6.69E+01 3.51E+03 0.0 2.28E+01 2.03E+06 2.28E+05 '
CE 141 2.84E+04 1.89E+04 2.16E+03 0.0 8.87E+03 6.13E+05 1.26E+05 ,
CE 144 4.88E+06 2.02E+06 2.62E+05 0.0 1.21E+06 1.33E+07 '8.63E+05 I l
l g TABIE 3.1-28 (1 of 1)
Rev. 28 1/1/90 l
f~['" ]
1 e ~ 'N TABLE 3.1-29
('# ) (1 of 1)
Rg VALUES - INEALATION PAT}NAY - CHILD NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG GI-LLI H 3 0.0 1.12E+03 1.12E+03 1.12E+03 1.12E+03 1.12E+03 1.12E+03 CR 51 0.0 0.0 1.54E+02 8.53E+01 2.43E+01 1.70E+04 1.08E+03 l
MN $4 0.0 4.29E+04 9.50E+03 0.0 1.00E+04 1.57E+06 2.29E+04 FE 55 4.73E+04 2.51E+04 7.76E+03 0.0 0.0 1.11E+05 2.86E+03 FE 59 2.07E+04 3.34E+04 1.67E+04 0.0 0.0 1.27E+06 7.06E+04 CO $8 0.0 1.77E+03 3.16E+03 0.0 0.0 1.10E+06 3.43E+04 )
CO 60 0.0 1.31E+04 2.26E+04 0.0 0.0 7.06E+06 9.61E+04 1
,ZN 65 4.25E+04 1.13E+05 7.02E+04 0.0 7.13E+04 9.94E+05 1.63E+04 SR 89 5.99E+05 0.0 1.72E404 0.0 0.0 2.15E+06 1.67E+05 SR 90 1.01E+08 0.0 6.43E+06 0.0 0.0 1.47E+07 3.43E+05 ZR 95 1.90E+05 4.17E+04 3.69E+04 0.0 5.95E+04 2.23E+06 6.10E+04 HO 99 0.0 1.73E+02 4.26E+01 0.0 3.93E+02 1.36E+05 1.27E+05 l SB 124 5.73E+04 7.39E+02 2.00E+04 1.26E+02 0.0 3.24E+06 1.64E+05 '
I 131 4.80E+04 4.80E+04 2.72E+04 1.62E+07 7.87E+04 0.0 2.84E+03
,m 1 133 1.66E+04 2.03E+04 7.68E+03 3.84E+06 3.37E+04 0.0 5.47E+03
, N s ,/ CS 134 6.50E+05 1.01E+06 2.24E+05 0.0 3.30E+05 1.21E+05 3.84E+03 l CS 136 6.50E+04 1.71E+05 1.16E+05 0.0 9.53E+04 3.45E+04 4.17E+03 CS 137 9.05E+05 8.24E+05 1.28E+05 0.0 2.82E+05 1.04E+05 3.61E+03 BA 140 7.39E+04 6.47E+01 4.32E+03 0.0 2.11E+01 1.74E+06 1.02E+05 i CE 141 3.92E+04 1.95E+04 2.89E+03 0.0 8.53E+03 5.43E+05 5.65E+04 CE 144 6.76E+06 2.11E+06 3.61E+05 0.0 1.17E+06 1.19E+07 3.88E+05 i,
I.
i TABLI 3.1-29 I fm (1 of 1) l i (s~ -)
Rev. 28 1/1/90 l
)
TABLE 3.1-30 O (1 of 1)
Rg M ES - I N TION PA M AY I N NUCLIDE BONE LIVER T. BODY THYROID KIDNEY LUNG GI LLI H 3 0.0 6.46E+02 6.46E+02 6.46E+02 6.46E+02 6.46E+02 6.46E+02 CR 51 0.0 0.0 8.93E+01 5.75E+01 1.32E+01 1.28E+04 3.56E+02 NN 54 0.0 2.53E+04 4.98E+03 0.0 4.98E+03 9.98E+05 7.05E+03 TE $5 1.97E+04 1.17E+04 3.33E+03 0.0 0.0 8.68E+04 1.09E+03 TE $9 1.35E+04 2.35E+04 9.46E+03 0.0 0.0 1.01E+06 2.47E+04 CO 58 0.0 1.22E+03 1.82E+03 0.0 0.0 7.76E+05 1.11E+04 CO 60 0.0 8.01E+03 1.18E+04 0.0 0.0 4.50E+06 3.19E+04 ZN 65 1.93E+04 6.25E+04 3.10E+04 0.0 3.24E+04 6.46E+05 5.13E+04 SR 89 3.97E+05 0.0 1.14E+04 0.0 0.0 2.03E+06 6.39E+04 SR 90 4.08E+07 0.0 2.59E+06 0.0 0.0 1.12E+07 1.31E+05 ZR 95 1.15E+05 2.78E+04 2.03E+04 0.0 3.10E+04 1.75E+06 2.17E+04 MO 99 0.0 1.65E+02 3.24E+01 0.0 2.65E+02 1.35E+05 4.88E+04 l SB 124 3.79E+04 5.55E+02 1.20E+04 1.00E+02 0.0 2.64E+06 5.90E+04 1 131 3.79E+04 4.43E+04 1.96E+04 1.48E+07 5.17E+04 0.0 1.06E+03 1 133 1.32E+04 1.92E+04 5.59E+03 3.55E+06 2.24E+04 0.0 2.15E+03 CS 134 3.96E+05 7.02E+05 7.44E+04 0.0 1.90E+05 7.95E+04 1.33E+03 CS 136 4.82E+04 1.34E+05 5.28E+04 0.0 5.63E+04 1.17E+04 1.43E+03 CS 137 5.48E+05 6.11E+05 4.54E+04 0.0 1.72E+05 7.12E+04 1.33E+03 BA 140 5.59E+04 5.59E+01 2.89E+03 0.0 1.34E+01 1.59E+06 3.83E+04 CE 141 2.77E+04 1.66E+04 1.99E+03 0.0 5.24E+03 5.16E+05 2.15E+04 CE 144 3.19E+06 1.21E+06 1.76E+05 0.0 5.37E+05 9.83E+06 1.48E+05 (1 of 1)
Rev. 28 1/1/90
-